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INTRODUCTION 
                Among the antique system of medicines, “SIDDHA” system is the south 
India’s admired system. The word “SIDDHA” is plagiaristic from the   word 
“SIDDHI” which means an entity to be headed for perfection or heavenly bliss. The 
SIDDHA system of medicine focused   on “ASHTAMAHASIDDHI” that is the eight 
supernatural powers, which helps to attain the DIVINITY. They are ANIMA, 
MAGHIMA, KARIMA LAHIMA, PRAPTHI, PRAHAMIYAM, ESATHUVAM, 
VASITHUVAM.  Those who achieved the above powers are known as “THE GREAT 
SIDDHARS” .There are many   siddhars lived and establish the system. Perhaps 18 of 
them are known to be important.  Those who were called as “18 SIDDHARS”. These 
legends wrote their knowledge in palm leaf manuscripts. These manuscripts developed 
as a constructive system of medicine in south India”.  By their supreme astuteness, 
they   wrote scriptures on all aspect of life, from arts to science and truth of life to 
miracle cure. 
Among them AGASTHYA is whispered to be a first siddhar directly thought 
by GOD.                
                  “ ¾ý¨É «È¢Âò ¾Éì¦¸¡Õ §¸Êø¨ Ä 
                 ¾ý¨É «È¢Â¡Áø ¾¡§É ¦¸Î¸¢ýÈ¡ý”. 
 
                                                       - ¾¢ÕãÄ÷ ¾¢ÕÁó¾¢Ãõ 
Know thyself and that makes you free from all evils but, man not knowing his 
own self becomes victim of all troubles. By preserving the health one can attain the 
IDOL.  That is the goal of our soul.  
                     “ THIRUMOOLAR”  one among  the 18 siddhars  quoted  in his book 
“THIRUMANTHIRAM”  which consist of  3000 poems ,mainly about the importance 
of health that let a way to conserve  the healthy soul. He coded the importance of 
health and  elucidate    how to prevent the body from diseases. He sophisticated his 
knowledge to other with the notion   that, “A HEALTHY SOUL CAN ONLY 
DEVELOPED BY A HEALTHY BODY “ 
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                                  “¯¼õÀ¡÷ «Æ¢Â¢ø ¯Â¢Ã¡÷ «Æ¢Å÷ 
                    ¾¢¼õÀ¼ ¦Áö»¡Éõ §ºÃ×õ Á¡ð¼¡÷ 
                    ¯¼õ¨À ÅÇ÷ìÌõ ¯À¡Âõ «È¢ó§¾. 
                    ¯¼õ¨À ÅÇ÷§¾ý ¯Â¢÷ÅÇ÷ò §¾§É” 
 
                                                                            - ¾¢ÕãÄ÷ ¾¢ÕÁó¾¢Ãõ  
 
                   Nowadays life style modifications and less physical works lead to many 
problems which are called as life style modification disorders. These sedentary life 
style results in DIABETES, HYPER TENSION, CARDIAC DISEASES,  E.T.C. 
The global prevalence of diabetes varies from 6.4% to 10.2%.   
   
There are numerous complications accompanied with diabetes. The major and 
most common   complication is diabetic poly neuropathy. In siddha system of 
medicine it’s correlated with vatha karshanam. 
   
             The disease “VATHA KARSHANAM” (DM NEUROPATHY)     tingling & 
numbness of palms & soles ,Glove and stocking type of anesthesia ,Calf muscle 
tenderness, Flaccid weakness of lower limbs and finally leads to foot drop . It is 
implicit as sixth and seventh avathaigal (complications) of MADHU MEGAM 
(DIABETES MELLITUS).   
The incident of DM NEUROPATHY is about 60% -70% of world diabetic 
population having mild to moderate NEUROPATHY. In world’s population about 
26% affected by diabetic neuropathy. The severity and incidence of neuropathy are 
especially great in blacks (3to 6 fold higher than whites. 
                 The complication of VATHA KARSHANAM (DM NEUROPATHY) are 
tropical foot ulcer, gangrene, neuropathic deformity, non-traumatic amputation. Most 
serious complication is , life style modification stress leads to isolation. 
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                    I presume that there is a correct time to give a very precise reinforcement 
for a worldwide disease VATHA KARSHANAM (DM NEUROPATHY) by our own 
soils medicine. Hence the authour prefers the drug “KARUNGALI VER KUDINEER 
“ to treat disease. Because the KARUNGALI VER (ACACIA CATECHU) has a 
capacity to reduces blood sugar levels stimulating the beta cells of langerhans  in 
pancreas and stabilizes the capillaries . And it has VITAMIN –B12 which rejuvenates 
the nerves. Thus i strongly believe that the drug will be a best elucidation for the 
worldwide disease. 
 
                   As per siddhars contemplation the diseases should be completely eradicate 
by a complete diet & life style modification. So i also included the diet regimen is a 
part of treating vatha karshanam.(DM NEUROPATHY) 
 
    “  Á¡ÚÀ¡ ÊøÄ¡¾ ¯ñÊ ÁÚòÐñ½¢ý 
       ëêÀ¡ Êø¨Ä ÔÂ¢÷ìÌ”. 
                                           
                                                  -¾¢ÕÅûÙÅ÷.                                       
              The food which is suitable for our body should be intaken. The food which 
pervert the ‘thiridhosa’ should be neglected.  This is the preventive methods ever since 
quoted long ago by one of the great saint THIRUVALLUVAR. 
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“HE WHO TAKES MEDICINE AND 
NEGLECTS TO DIET WASTES THE 
SKILL OF HIS DOCTOR”         
                                    -CHINESE PROVERB                                                                   
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AIM & OBJECTIVE 
PRIMARY AIM:  
      To evaluate the safety and efficacy of KARUNGALI VER KUDINEER. 
SECONDARY AIM:  
            The aim of my study is to evaluate the efficacy of the trial drug  
KARUNGALI VER KUDINEER in VATHA KARSANAM (DM NEUROPATHY) 
OBJECTIEVES: 
• To amass the literature of both siddha and modern aspect of the disease 
VATHA KARSHANAM 
• To revise the clinical course of the disease VATHA KARSHANAM with  
deep scrutiny on etiology,  patho physiology , pathology, diagnosis, 
differential diagnosis, complication and treatment by siddha aspect. 
• To depict the clinical diagnostic  methods  practised by siddhars to  
distinguish the dearrangements of  mukkutram,  examine the pori pulangal, 
udal katugal, neerkuri, nei kuri as per the envagai thervugal. 
• To have an idea about the incidence of disease with age, sex, occupation, 
economic status, habits, familial history, previous history, and climate 
variations 
• Detailed clinical investigation 
• To  study the efficacy of the drug  KARUNGALI VER  KUDINEER  
• To evaluate the safety of the drug 
• To find out the biochemical analysis of the trial drug. 
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SIDDHA ASPECT 
                   In siddha system of medicine, according to the derangements of 
thiridhosas, ( vatham, pittham, iyyam)  diseases are classified into 4448 types. The 
treatment is not only for the physical body’s pathology but also for the spiritual mind 
   
Á¢¸¢Ûõ Ì¨ÈÂ¢Ûõ §¿¡ö¦ºöÔõ á§Ä¡÷ 
ÅÇ¢ Ó¾Ä¡ ±ñ½¢Â ãýÚ 
-¾¢ÕÅûÙÅ÷ 
 
 
VATHAM: 
Synonyms: 
                    Vayu, vali, Arasan. 
 
Definition: 
                       Vadham or vali is not mere wind but also causes motion, energy and 
sensation of every cell in the body. Vayu, one amongst the uyir thathukal and 
panchapootham(five elements of earth) . Human life  is classified in to three phases. 
• VAZHI- early phase 
• Azhal- middle phase 
• Iyam- last phase 
 
Å¡¾Á¡ö  À¨¼òÐ À¢ò¾ ÅýÉ¢Â¡ö ¸¡òÐ 
                          §ºòÁ º£¾¨Á Ð¨¼òÐ 
                                        - §¾Ãý ÁÕòÐÅ À¡Ã¾õ 
 
               Vatham is responsible for edifice of works and movements of various parts 
of our body. When the vilation of vali kuttram produces 
    
• Pricking 
• Gnawing 
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• Tingling pain 
• Loss of functions of affected areas at later stage 
         
DEFINATION: 
                     It is defined as, whenever the vatha kuttram exceeds or decreased in its 
level it shows the symptoms likes, pricking and irritating pain, disability to do works, 
tremors, and e.t.c. 
ETIOLOGY: 
      According to yugi sinthamani, 
• Excess intake of bitter, sour, and spicy food 
• Old food intake 
• Long term constipation, 
• Hiccough  
• Irregular food habbits 
  VATHA KARSANAM  is classified under the 80 
types of vatha noi or vazhi noi by the great siddhar 
YUGI MUNIVAR in his literature YUGI VAITHIYA 
SINTHAMANI 
±ýÉ§Å Å¡¾ó¾¡ ¦ÉñÀ ¾¡Ìõ 
     Á¢¸ò¾¢§Ä ÁÉ¢¾÷¸Ùì ¦¸öÐ Á¡Ú 
           À¢ýÉ§Å ¦À¡ó¾¨É§Â §º¡Ãï ¦ºöÐ 
      ¦À¡¢§Â¡÷¸û À¢Ã¡Á½¨Ãò à„ ½¢òÐõ 
ÅýÉ§Å Åî¦º¡ò¾¢ü §º¡Ãï ¦ºöÐ 
       Á¡¾¡À¢¾¡ ÌÕ¨Å ÁÈóÐ §À÷ìÌõ 
           ¸ýÉ§Å §Å¾ò¨¾ ¿¢ó¨¾¦ºö¾ §À÷ìÌõ 
        ¸¡Âò¾¢ü ¸Äó¾¢Î§Á Å¡¾ó ¾¡§É. 
- À¡¼ø243  Àì¸õ 183 
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             ¾¡¦ÉýÈ ¸ºô§À¡Î ÐÅ÷ôÒ ¨ÃôÒ 
º¡¾¸Á¡ö Á¢ïÍ¸¢Ûï º¨Áò¾ ÅýÉõ 
                        ¬¦Éý§È« Å¡È¢óÐ ¦À¡º¢ò¾ Ä¡Öõ 
                              ¬¸¡Âò §¾ÈÄÐ ÌÊò¾ Ä¡Öõ 
                         À¡¦ÉýÈ À¸ÖÈì¸ Á¢Ã¡Å¢ Æ¢ôÒ 
ÀðÊÉ¢§Â Á¢¸×Ú¾ø À¡Ã ¦Áö¾ø 
                         §¾¦ÉýÈ ¦Á¡Æ¢Â¡ü§Áü º¢ó¨¾ Â¡¸¢ø 
º£ì¸¢ÃÁ¡ö Å¡¾ÁÐ ¦ºÉ¢ìÌó ¾¡§É. 
 
                                               - À¡¼ø243  Àì¸õ 183 
 
..................................................................... 
............................................................ 
¬½¡É ÅÃýÈ¨É§Â Á¾¢Â¡ Á¡ó¾÷ 
«¸¾¢ÀÃ §¾º¢Â÷¸ð ¸ýÉ Á£Â¡÷ 
§¸¡É¡É ÌÕ¦Á¡Æ¢¨Â ÁÈó¾ §À÷¸û 
¦¸¡¨Ä¸Ç× ¦À¡ö¸¡Áí  ÌÈ¢ò¾ §À÷ìÌõ 
°É¡É º¼ó¾ýÉ¢ø Å¡¾õ ÅóÐ 
¯üÀÅ¢ìÌõ §Å¾ò¾¢ Ññ¨Á ¾¡§É. 
 
                               - À¡¼ø243  Àì¸õ 183 
                                                            - ä¸¢ ¨Åò¾¢Â º¢ó¾¡Á½¢(§¿¡ö ¿¡¼ø 600) 
 
According to sadhaga naadi: 
• Seasonal attacks ( winter season) 
 
¸¼¸Ó¾ø ÐÄ¡õ Å¨ÃÂ¢ø Å¡¾Á¡Ìõ 
¸ñ½¡Ê ¨ÂôÀº¢Ô ÁÐ§Å Â¡Ìõ 
                                                             º¾¸ ¿¡Ê( §¿¡ö ¿¡¼ø 596) 
According to noai nadal, 
• Excess alcohol, toddy intake 
• Diabetes mellitus(mega noi) 
• Cardiac diseases 
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ACCORDING TO T.V. SAMBASIVAM PILLAI  
 
                    Vatha karshanam is a disease which defined as a disease of the foot 
caused by the vitiated wind humour marked by numbness of the part and inability to 
bend or stretch and a feeling of something sticking to the foot and enlargement of the 
limb. 
                                               -T.V.SAMBASIVAM PILLAI AGARATHY 
                                                                        VOL - V   PAGE-1044  
ACCORDING TO THERAYAR VAGADAM: 
                  
 
Å¡Ô §¸¡À¢ò¾¡ø ºóÐ «¨ÇóÐ ¾¨Ä§¿¡Å¡õ 
Á¢ì¸Ó÷ ¦¸¡ð¼¡Å¢ Å¢ð¼Ð ¦¸¡¢Â ÁÄí¸ðÎõ 
     ´ì¸ ¿ÃõÒ ¾¡ý Ó¼í¸ ãÄÁóÐ Å¡ö ¿£ÕÈ¢ÅÕõ 
     Á¢ì¸ ÌÇ¢Õõ ¿Îì¸Á¡õ §ÁÉ¢ ÌýÈ¢ ÅÕí¸¡§½ 
 
                                          -Àì¸õ 76 
 
 Pain in the joints 
 Headache 
 Excessive yawning 
 Constipation 
 Excessive salivation 
 Burning sensation of the body 
 Chillness and tremor. 
  
ACCORDING TO AGASTHIYAR GUNAVAGADAM: 
     
¦¾¡ø¨Ä ¦ºöÂ þýÛõ¦ÅÌ Å¡¾§¿¡ö¸û 
¦¾¡øÖÄ¸¢ø Á¡ó¾ÕìÌ ¸¡ñÀÐñÎ 
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±ø¨ÄÂ¢øÄ¡ Å¡¾§¿¡ö¸û §¿÷¨Á ¾ý¨Á 
þÂøÀ¡¸ «È¢ó¾¢¼§Å Å¢ÀÃí§¸§Ç 
 
 
                         Å¢ÅÃÁ¼¡ «º¾¢ºýÉ¢ ã¨Ç §¿¡× 
                                    Å¢¡¢Å¡É ã¨ÇÂÐ Á¢ÕÐÅ¡¸¢ 
                         «ÅÉ¢¾É¢ø ¾¢¼Á¡¸ô §À¡Å¾¡Öõ 
              «ôÀ§É ãò¾¢Ãì ÌñÊì¸¡ö Å¢Â¡¾¢Â¡Öõ 
 
                            ¾¡ÅÓÉ¢Å÷ ¾£÷¸¡ì¨¸ §Á¸§Ã¡¸õ 
               ¾ý¨ÁÔûÇ Óò¾ñÎì ¦¸¡Ê Å¢Â¡¾¢ 
                          «ÅÁ¢Ä¡ô À¡¡¢º ¿ÃõÀØò¾í ¸ñ¼¡ö 
        «ÏÌÁ¼¡ Å¡¾§¿¡ö ¬Ìõ À¡§Ã 
 
                          «ÏÌÁ¼¡ Á¡Á¢ºò¾¢ý Å¢Â¡¾¢Â¡Öõ 
«ôÀ§É Ý¾¸ò¾¢ý ¦ÀÕì¸¡Öõ 
                           Ì½Á¢øÄ¡ þÃºõ Åí¸õ ¾¢ýÉ¡Öõ 
ÌÊ¦¸Îò¾ Å¡¾ÁÐ ¯ñ¼¡ÁôÀ¡ 
 
                                               - Àì¸õ 16 
 
 Brain disease 
 Kidney diseases 
 Sexually transmitted diseases 
 Vertebral column & spinal diseases 
 Menorrhagia 
 
  
 
 
ACCORDING TO THERAYAR MAHAKARISAL, 
         
                               ¬¸í ¸ÚìÌ §¿¡ Â¡¸óÐÊìÌõ 
                ¬È¡ò¾£ ¦ÂýÉ¦Áö §Â¸í ¦¸¡¾¢ìÌõ 
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¬Õ¦Áö Å¢Â÷¾¢Á¢÷ Á£¾ó¾õ Å¡öãîÍ 
¬Ì§ÁÂ¢Ð Å¡¾ §ÁÄ¢É¢ 
 
                                                                                        -  Àì¸õ 15 
 
 Discolouration of normal skin 
  Burning sensation of body 
 Sweating 
 Numbness 
 Dyspnoea 
 
 
ACCORDING TOPARARASASEKARAM: 
 
¦¾¡Æ¢ø ¦ÀÚ¨¸ôÒì ¸¡÷ò¾ø ÐÅ÷ò¾ø Å¢ïÍ¸¢Ïï §º¡Úõ 
À¨ÆÂ¾¡õ ÅÃÌ Áü¨ÈÂô ¨Àó¾¢¨½ ÂÕó¾¢É¡Öõ 
            ±Æ¢ø ¦ÀÈô À¸ÖÈí¸¢ þÃÅ¢É¢ ÖÈí¸¡¾ ¾¡Öõ 
Á¨Æ¿¢¸÷ ÌÆÄ¢É¡§Ç Å¡¾í§¸¡ À¢ìÌõ ¸¡§½. 
                                           -Àì¸õ-12 
 
 Consumption of excessive 
 Astringent 
 Savouries 
 Cereals 
 Rancid food 
 Day time sleep 
 Lacking night sleep 
 Increases  vatha kuttram 
ACCORDING TO AGASTHIYAR GUNAVAGADAM: 
 
                          «õÒÅ¢Â¢ø Å¡¾§¿¡ö ÅÕÌõ §¿÷¨Á 
«ôÀ§É ¦º¡øÖ¸¢§È ÉÈ¢Å¡öì §¸Ù 
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                           ¦¾õÒ¼§É ´¡¢¼ò¾¢ §ÄÛ ÁôÀ¡ 
¦¾Ç¢Å¡¸ô ÀÄÅ¢¼ò¾¢ §ÄÛ ÁôÀ¡ 
                           ºõÀ¢ÃÁ¡öô À¡¢º ¿ÃõÀ¢ §ÄÛ 
                                  º¾¢Ã¡É ºÄÉ ¿ÃõÀ¢ §ÄÛ ÁôÀ¡ 
                            ¸õÀ¢¾Á¡ Â¢ÃñÎ ÁøÄ¡Áü §À¡É¡ø 
        ¸Ê¾¡É Š¾õÀÉ§Ã¡¸ ¦Áý§È ¦º¡øÅ¡ö 
 
                                       - À¡¼ø121 Àì¸õ31 
 
 This poet is the evidence for, that vadha diseases may occur in a single or many 
places. 
 Vatham may affect both the sensory and motor nerves. 
 
 
 
ACCORDING TO AGASTHIYAR KANMA KANDAM300: 
 
                        á¦ÄýÈ Å¡¾õ Åó¾Å¨¸ ¾¡§ÉÐ 
Ññ¨ÁÂ¡öì ¸ýÁò¾¢ý Å¨¸¨Â §¸Ù 
                       ¸¡Ä¢§Ä §¾¡ýÈ¢ÂÐ ¸ÎôÀ §¾Ð 
                              ¨¸¸¡Ä¢§Ä Ó¼í¸¢ÂÐ Å£ì¸¦ÁÐ 
                       §¸¡Ä¢§Ä ÀÎì¸¢ýÈ Å¢ÕðºÁ¡É 
       ÌÆó¨¾ ÁÃó¾¨É ¦Åð¼ø §Áø§¾¡ø º£Åø 
                       ¿¡Ç¢§Ä º£Å¦ºóÐ ¸¡ø ÓÈ¢ò¾ø 
¿øÄ ¦¸¡õÒ ¾¨ÆÓÈ¢ò¾ø ¿øò¾ø ¾¡§É 
 
                                    - Àì¸õ13 
 Removing the barks of living trees 
 Causes grievous injuries to animals 
are the reasons for causing vatha diseases. 
  
ACCORDING TO KANNUSAMYAM: 
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§Á¸ò¾¢ø ¿£¡¢Æ¢× §Á×Á¾¢ø Å¡¾§¿¡ö...... 
 
                               -À¡¼ø 59, Àì¸õ18 
 
In megha rogam, madhumegam(diabetes mellitus) causes vatha noi. 
  
ACCORDING TO THERAYAR SEKARAPPA: 
 
À¢½¢ Âð¼Å¨½ ¦ºôÒ§Åý ¸Õô¦À¡ÕÇ¢ 
                            ÁÐ§Á¸¦Á¡¢ §Ã¡¸í Å¡¾...... 
 
                                                                  -  Àì¸õ45 
 
NOI EN (CLASSIFICSATIONS): 
 
The classification of vatha diseases is varied  amongst the siddhars. Some them re 
quoted below 
 
 According to yugivaithiya sinthamani, vatha diseases are classified in to 80 
types . 
 
                         “ ±ýÉ§Å Å¡¾ÁÐ ±ñÀ ¾¡Ìõ 
²üÈÁ¡õ §ÀÕ¨¼Â ±Æ¢¨Äì §¸Ç¡ö 
                           ÅýÉ§Å Å¡¾Š¾õÀõ Å¡¾ ¸÷„½õ 
Å¨¸Â¡É ¸ÃŠ¾õÀó ¾ÄŠ¾õ Àó¾¡ý 
                                      ¦À¡ýÉ§Å âÍÅ¡ ¾ò¾¢ §É¡Î 
¦À¡¢Â¸¡ Ç¡ïº¸Ó ãÕ Š¾õÀõ 
ÌýÉ§Å Å¡¾¸÷ýÉí Ì¡¢„ ¸¢¡¢„õ 
ÜÈ¡É ¿¡¢ò¾¨ÄÂ¢ý Å¡¾ Á¡§Á” 
 
                            ¾¨ÄìÌõÀ Å¡¾¦Á¡Î Á¨Äò¾ ¸õÀõ 
¾Õì¸¡É À¡½¢¸õÀí ÜÉ¢ Å¡¾õ 
                            «¨ÄÂ¬ ÌÉ¢Å¡¾õ «§„À ¸ó¾¡ý 
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«¾¢Å¡¾õ ¯À¸¾Óõ ¦¿üÈ¢ Ý¨Ä 
                            ¸¨ÄÂ¡É Ý¨Ä¦ºÅ¢ ÀÎÅ¡ Â¡Ìõ 
¸ÎÀì¸ Å¡¾¦Á¡Î À‡ Å¡¾õ 
¾¢¨ÄÂ§Àö Å¡¾¦Á¡Î À¢Ã¡½¡ ÄÂó¾¡ý 
                  ¾Õì¸¡É ºÄŠ¾õÀ¦Á¡Î ºóÐÅ¡¾ Á¡§Á. 
 
                         ºóÐÅ¡ ¾ò§¾¡Î º¸É Å¡¾õ 
                               ¾¡¢ò¾Åü Ò¾Å¡¾ ÓÃ¸ý Å¡¾õ 
                         ¯óÐÓÃ ¸¡¡¢§Â¡Î Å¡ŠÅ  ¾õÀõ 
¯Ú¾¢À¡ ºò¾õÀõ §¿ò¾¢Ã À×ò¾¢Ãõ 
                         «óÐ¾ñ¼ Å¡¾¦Á¡Î Å‰¼ò ¾ó¾¢Ãõ 
«¾¢ÅºÉ¡ Å¡¾¦Á¡Î Á¸¡Å¡ ¾ó¾¡ý 
                          ÓóÐÁ¢ÕóÐ Å¡¾§Á¡ Î¾Ã Å¡¾õ 
Ó¸¢úãò ¾¢Ã×¾¢Ã Å¡¾Á¡ ¦Áý§É. 
 
                         ±ýÈÍì¸¢Ä Å¡¾ïºù Å¢Ãí¸ Å¡¾õ 
              ±Æ¢Ö°÷òÐÅ Å¡¾¦Á¡Î Åï»¡Éò ¾õÀó 
                        ¦¾ýÈº¢Ãì ¸õÀÅ¡¾ Óïº¾Š ¾õÀõ 
¦ºÂÅîº¢Ã åÀ¦Á¡Î ¸ñ¼ì ¸¢Ã¡¸õ 
                        ¿ýÈ¾¡õ ¿¸¡¡¢¦Â¡Î À¾¢¾ Å¡¾õ 
¿Ä¢§Â¡É¢ Ý¨Ä¦Â¡Î ¦¸÷ôÀ Ý¨Ä 
                        ÌýÈÅ‰¼ Ý¨Ä¦Â¡Î Ì¼øÅ¡ ¾ó¾¡ý 
ÌÈ¢ÂÍÅ Å¡¾¦ÁîÍ Å¡¾ó ¾¡§É. 
 
                         ¾¡ýãÎ Å¡¾Á¡õ ÅÍÅ¡ ¾ó¾¡ý 
¾ÛÀ£ƒò ¾õÀ¦Á¡Î ¾ó¾¢Ã ¦ÅðÊ 
Å¡ýÅ¡¾ Í§Ã¡½¢¾ï º¢òÐÅ¡¾Í §Ã¡½¢¾õ 
Á¸ò¾¡É ¨Å¸¢¾ Å¡¾îÍ §Ã¡½¢¾õ 
                          °Û¾¢Ã Å¡¾Í§Ã¡ ½¢¾ó¾ý §É¡Î 
¯ÚÀÂ¢ò¾¢Â Å¡¾Í§Ã¡ ½¢¾Ó Á¡Ìõ 
§¾ýº¢§ÄðÎÁ Å¡¾Í§Ã¡ ½¢¾ó¾¡ý Á¢ì¸Š 
º¢óòÐ¾Ã Å¡¾Í§Ã¡ ½¢¾Óí ¸¡§½. 
 
                                ¸¡½§Å Ì½ÅÅ ¾¡É¸Á¡õ Å¡¾í 
¸ñ¼¸Å ¾¡É¸Á¡õ Å¡¾ Á¡Ìó 
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                              §¾½§Å º¢Ãì¸õÀ ÅÅ¾¡É ¸ó¾¡ý 
      º£È¢Â§¾¡÷ Å¡¾ò¾¢ý È¨Ä§¿¡ì ¸¡Î 
                              â½§Å À¢ò¾ò¾¢ý È¨Ä§¿¡ì ¸¡Î 
            Ò¸Æ¡É º¢§ÄðÎÁò¾¢ý È¨Ä§¿¡ì ¸¡Î 
º¡½§Å ºýÉ¢Å¡¾ò¾¢ý È¨Ä§¿¡ì ¸¡Î 
         ¾ÕÃò¾ À¢ò¾ò¾¢ý È¨Ä§¿¡ì ¸¡§¼. 
 
 
                          §¿¡ì¸¡É ¸¢ÕÁ¢¸ó¾ ¾¨Ä§¿¡ì ¸¡Î 
Ñ¾üÝ¡¢Â¡ Å÷ò¾¦Á¡Î ºó¾¢Ã¡ Å÷ò¾õ 
                          °ì¸¡ý ¸÷É¡Å¡  ¾ó¾ý §É¡Î 
                               ´Õ¾¨ÄÂ¢ý Å÷ò¾Å¡ ¾Ó§Á Â¡Ìõ 
                        Å¡ì¸¡É Å¡¾¸÷É Ý¨Ä §Â¡Î 
ÁÕÅ¢Â§¾¡÷ À¢ò¾¸÷É Ý¨Ä Â¡Ìó 
                         §¾ì¸¡É º¢§ÄðÎÁ¸÷É Ý¨Ä §Â¡Î 
¦ºÂÁ¡É ¸¢ÕÁ¢¸÷É Ý¨Ä ¾¡§É. 
 
 
                            ¾¡É¡É ¾ó¾Å¡ ÔÅ¢ýÈý §É¡Î 
¾¡ì¸¡É Å¡¾ó¾¡ý ±ñÀ ¾¡Ìõ. 
 
 Bogar  classified into 80 types 
Å¡î¦ºýÈ Å¡¾õ ±ñÀÐ×õ §À¡Ìõ 
 
                                     - §À¡¸÷ ¨Åò¾¢Âõ 700 
  
 ACCORDING TO PARARASASEGARAM: 
     
µ¾¢Â Å¡¾ ¦Áñô ¾¢ý Ì½ ÓÚ§À÷ 
 
                             -À¡ÃÃ¡º§º¸Ãõ 
 
 ACCORING TO AGASTHIYAR: 
          
27 
 
±ñÀÐ Å¡¾Á¡Ì Á¢ÕÅ¨¸ôÀÎò¾¢ì ¸¡½¢ý 
¿ýÒÚ «¨ÃìÌ §Á§Ä ¿¡üÀÐ Å¡¾Á¡Ìõ 
Àñ§ºÃ¨ÃìÌ ¸£§Æ ÀòÐ ¿¡ý¸¡Ìõ ¦ÁýÚ 
     ÅñÎ§º÷ ÌÆÄ¢É¡§Ç Å¡¾ò¾¢ý ÜÚ¾¡§É 
 
  -«¸ò¾¢Â÷ 2000 
 
 
 
                             ÁüÈ§Á Å¡¾§Ã¡¸õ Å¨¸ ±ñÀòÐ ¿¡§Ä 
                
                                                                                   - «¸ò¾¢Â÷ Ãò¾¢É ÍÕì¸õ 
 in,agasthiyar guru nadi nool, 
  
                         vadha diseases are classified as 84 types. 
 
 
 
ACCORDING TO YUGI in his another book  : 
 
 
                      ¬ÁôÀ¡ Å¡¾õ ¦¾ñÀòÐ ¿¡Ö 
«¾Û¨¼Â Ì½¡Ì½í¸ Ä¼í¸Ä¡¸ 
 
 
                                     -  ä¸¢ ¨Åò¾¢Â º¢ó¾¡Á½¢ 800 
 
 In JEEVA RATSHAAMIRTHAM  - 80 types 
 In THERAYAR GUNAVAGADAM-81 types 
 In, SARAGASAMHITHAI-2nd part  -80 types 
 In, ASHTANGA SANGHIRAGAM-85 types. 
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   VATHA KARSANAM 
                  Vatha karsanam is one among the 80 types of vatha noigal. The major 
symptoms are pain and numbness over the sole of the foot, irritating pain in both 
extremities that pain radiates to the whole parts of body 
Å¡¾ ¸÷ºÉõ 
 
À¡÷ì¸¢ýÈ Å¡¾×û ÇÊÂ¢ü º¡½¢ 
À¾¢òÐ¨Åò ¾Ð§À¡Äô À¡¾ ¦ÁíÌõ 
§¿¡ì¸¢ýÈ Ì¾¢ÉÃõÒì ¸¡ø¸  ¦ÇíÌõ 
¦¸¡Ê¾¡É À¡ÃÁ¡öò ¾¢Á¢÷ô Òñ¼¡¸¢ 
Å¡÷ì¸¢ýÈ Å¡÷ò¨¾¸û Á¢¸§Å ¦ºöÐ 
Å¨Çó¾¢ÊÛõ ¿¢Á¢÷ó¾¢ÊÛõ Åºí§¸¡ ¼¡Áø 
²÷ì¸¢ýÈ ¸¡Ö¨ÇìÌõ Å¡¾  ¸÷ºÉõ 
®¾ÄÈ Á¢øÄ¡¾¡÷ì ¦¸öÐíì  ¸¡§½. 
±ýÀ¾¡ø, þ¾¢ø ¸¡ÄÊÂ¢ü º¡½¢¨Âô âº¢ÂÐ §À¡ýÚ«ÕÅÕô¨À ¯ñ¼¡ì¸¢ì 
Ì¾¢ì¸¡ø ¿ÃõÀ¢ø ÅÄ¢Ôõ, ¸¡ø¸û ¸ÉÁ¡¸×õ, ¸¡Ä¢ø ÅÄ¢Ôõ ¾¢Á¢Õõ ¸¡Ïõ. 
¯¼¨Ä Å¨Çì¸×õ ¿¢Á¢÷ì¸×õ ÓÊÂ¡¾Å¡Ú §¿¡Ìõ. 
 
According to tamil lexicon dictionary vol II  
                                        KARSANAM means - burning sensation  
 ¸¡ÄÊÂ¢ü º¡½¢¨Âô âº¢ÂÐ §À¡ýÚ «ÕÅÕô¨À-numbness  over the soles 
 Ì¾¢ì¸¡ø ¿ÃõÀ¢ø ÅÄ¢ - nerve pain in lower limbs. 
 À¡ÃÁ¡ö ¾¢Á¢÷ôÒñ¼ì¸¢  -numbness over the palms and soles 
 ¸¡Ö¨ÇìÌõ- burning sensation  
 
 
 
 
MUKKUTRA VAERUPADUGAL :( Pathogenesis) 
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                                       ¯ûÇ§¾¡÷ ¯¼Ä¢ý ÜÚ 
¯ÚôÒ¸Ù¼ý Å¢ÃÅ ¿¢ýÚ 
                                      ÓüÚ§Á §¿¡ö¸û Â¡×õ 
Ó¾Ä¢É¢§Ä §¾¡ýÚõ §À¡Ð 
                                     ÀüÚ§Á Å¡¾ À¢ò¾ 
           º¢§ÄüÀÉó¾Éó ¾ýÉ¢ø «Åü¨È 
                                      ÀüÈ¢§Â §¾¡ýÚ ¦ÁýÚ 
À¸÷¾É÷ ÓÉ¢Å÷ ¾¡§Á 
                                           -«ìò¾¢Â÷ ÌÕ ¿¡Ê 
Disease occurs due to the derangement in 
•  Uyir thathukkal  
•  Udalthathukkal   
•  kala marupadu(seasonal changes) 
• Thinai( living lands ) and 
• Udal vanmai. 
 
Mukkutra Iyal : 
The function of the three uyir thathus:  
a) Vali   –  (Kattru + Veli) 
 
b) Azhal   – (Thee) 
 
c) Iyyam   – (Neer+Mann) 
  
              The alteration of three thathu in their reaction to extrinsic or intrinsic factors 
results in disharmony. This altered harmony and balance variation of the three thathus 
results in disease. Their natural ratio (1 :½:¼) to each other is discerned by the 
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physician at the wrist and each nadi is individually assessed for its strength, speed and 
regularity. 
The following poem describes the origin of three uyir thathus 
‘,Ug;ghd ehb vOgNjhBuh 
 
 apukhd Njfj;jpy; Vyg; -ngUehb 
 
 xf;fj; jrkj; njhopiy a+f;f jrthAf;fs; 
 
 jf;fgbahdNj  rhu;G” 
       ‘rhUe; jrehb jd;dpy; %yk; %d;W 
  
 NgUkplkp gpq;fiyAk; gpd;dYld;-  khWk;  
 
 ciuf;ftpuw; fhw;nwhl;Lzu;j;J Nkehrp 
 
                     The three Thathus are manifested at the wrist and are individually and 
collectively assessed. These three humour are divided in to various types and have 
their functions specifically. 
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VATHAM 
FUNCTIONS OF VALI: 
‘xOq;Fls; jhNjo;%r; Nrhq;fp ,aq;f 
 
vOr;rpngw vg;gzpAk; Mw;w - vOe;fpupa 
 
Ntfk; Gyd;fSf;F Nktr; RWRWg;G 
 
thfspf;Fk; khe;ju;f;F thA” 
- kUj;Jt jdpg;ghly; 
The term vatham denotes vayu, dryness, pain and flatulence. Based on functions and      
locations it is classified in to 10types. They are tabulated below  
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S.NO 
                  
          VATHAM 
           
      GENERAL 
FEATURES 
 
Changes in  
1. Piranan  Responsible for respiration 
and it is necessary for 
proper digestion  
Normal 
2. Abanan Responsible for  all 
downward forces such as 
voiding of urine, stools, 
semen, menstrual flow  
Affected due to poly 
uria. 
3. Viyanan(paravukaal) Dwells in the skin and is 
concerned with the sense of 
touch... extension and 
flexion of the parts of the 
body and distribution, of 
the nutrients to various 
parts of the body 
Affected due to pain 
& numbness 
4. Uthanan 
(melnokkukaal) 
Responsible for all kinds of 
upward motion such as 
nausea, vomiting etc... 
Normal  
5. Samanan(nadukkaal) Considered essential for 
proper digestion, 
assimilation and carries the 
digested nutrients to each 
and every organ 
Affected  due to poly 
phagia 
6. Nagan  Helps in opening &closing 
of eyelids 
Normal  
7. Koorman  Responsible for vision, 
lacrimation  and yawning 
Affected due to vision 
impairment 
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8. Kirugaran Induces  appetite, 
salivation, all secretions in 
the body including nasal 
secretion and sneezing 
Normal  
9.   Thevathathan  Induces and stimulates a 
person to become alert, get 
anger, to quarrel, to sleep 
etc 
Affected due to 
weakness 
10. Dhananjeyan  Resides in the cranium and 
produces bloating of the 
body after death. This 
leaves from the body after 
3days of death, forming a 
way through the skull. 
   
 
 
-------- 
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PITHAM 
 
FUNTIONS OF AZHAL: 
 
 ‘grpjhfk; Xq;nfhspfz; ghu;itgz; lj;J 
 
 Urpnjup rj;jp ntk;ik tuk; - crpj 
 
 kjp$u;j;j Gj;jptdg; gspj;Jf; fhf;Fk; 
 
 mjpfhup ahq;fh doy;” 
                             kUj;Jt jdpg;ghly; gf;fk;16                                                                                                                        
 
It is the thermal life force of the body. It is subdivided into five types. They are 
S.NO PITHAM  NORMAL FEATURES CHANGES IN 
1. Anarpitham  Peps up the appetite and aids in 
digestion. 
Affected due to poly 
phagia 
2. Ranjagapitham  Responsible for the colour and 
contents of blood. 
Affected due to anaemia 
3. Sathagapitham Controls the whole body and is held 
responsible for fulfilling a purpose. 
Affected due to 
generalised disability 
4. Pirasagapitham  Dwells in the skin and concerned 
with the shine, glow, texture and its 
complexion 
Normal  
5. Alosagapitham  Responsible for the perception of 
vision. 
Affected due to vision 
disturbance 
 
                                                  KABHAM 
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FUNTIONS OF IYAM: 
‘jplkPA nkd;gpizg;Gj; jpz;ikAw;w ahg;Gk; 
 
mlNyu; tOtOg;Gk; Mf;iff; - fplu;f;F 
 
ntUthg; nghWikAk; Nkyhd fhg;ghk; 
 
ngUikj;jh ikankdg; NgR” 
                            -kUj;Jt jdpg;ghly; gf;fk;20 
                                               It is responsible for the stream lined functions of the body 
and maintains body’s defence mechanism intact. It is again classified into 5 types. 
S.NO   KABHAM GENERAL FEATURES CHANGES IN 
1. Avalambagam  Lies in the respiratory organs, 
exercises authority over other khapas 
and controls the heart and circulatory 
system. 
Normal  
2. Kilethagam  Found in stomach as its seat, moistens 
the food, softens and helps to be 
digested. 
Affected due to poly phagia 
3. Pothagam  Hold responsible for the sensory 
perception of teste. 
Normal  
4. 
 
 
Tharpagam  Presents in the head and is responsible 
for the coolness of the eyes, sometimes 
may be referred to as cerebrospinal 
fluid 
Affected due to vision 
impairment 
5. Santhigam  Necessary for the lubrication and the 
free movements of joints. 
Affected due to joint pain 
 
                                                       UDAL KATTUGAL 
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S.NO UDAL KATTUGAL GENERAL FEATURES CHANGES IN  
1. Saaram 
 (digestive essence) 
Responsible for the growth& 
development. It keeps the 
individual in good temperament 
and it enriches the bood. 
Deranged due to 
physical and mental 
disability  
2. Senneer (blood) Responsible for the colour of 
blood and for the intellect, 
nourishment, strength, vigour 
and valour of the body.  
Deranged due to 
increased blood sugar 
3. Oon (muscle) Gives lookable contour to the 
body as needed for the physical 
activity. It feed the fat next day 
and gives a sort of plumpness to 
the body  
deranged 
4. Kozhuppu (fat) Lubricates the organs to 
facilitate frictionless functions. 
Normal 
5. Enbu (bones) Supports & protects the vital 
organs, gives the definite 
structure of the body and 
responsible for the posture and 
movements of the body 
Affected in joint pain 
in some patients 
6. Moolai (bone marrow) Nourishes the bone marrow and 
brain which is the centre that 
controls other systems of body 
Normal  
7. Sukkilam/ Suronitham(sperm/ 
ova) 
Responsible for reproduction Normal  
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      PARUVAKALAM 
   
S.NO PERUM POZHUTHUGAL MUKKUTTRA   MARUPAADUGAL 
1. Kaar kaalam  
(Aavani & purattasi) 
Aug 16 to Oct15 
VATHAM-vettunilai vazharchi 
PITHAM-thanilai vazharchi 
2. Koothir kaalam 
(Iypasi &karthigai) 
Oct 16 to  Dec15 
VATHAM- thanilai vazharchi 
PITHAM- vettunilai vazharchi 
3. Munpani kaalam 
(Margazhi & Thai) 
Dec16 to Feb15 
PITHAM- thanilai vazharchi 
4. Pinpani kaalam 
(Masi& Panguni) 
Feb16 to June15 
KABHAM- thanilai vazharchi 
5. Elavenir kaalam 
(chithirai & vaikaasi) 
April16 to June15 
KABHAM- vettunilai vazharchi 
6. Mudhuvenir kaalam 
Aani & Aadi 
June16 to Aug 15 
VATHAM- thanilai vazharchi 
THINAI (LAND): 
            Siddhars classified the lands in to five types. They are 
1. Kurunchi    - Mountain range 
2. Mullai         -Pastoral area of the forest 
3. Marudham -The fertile river bed  
4. Neidhal      -The coastal region 
5. Paalai         - Arid desert                                                                     
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RELATION BETWEEN MUKKUTRAM, KAALANGAL AND THINNAIGAL     
 
 
 
 
 
 
 
 
VATHAM 
 
 
Mudhuvenil 
kalam 
 
 
Kaar kalam 
 
 
 
 
Koothir kalam 
 
 
Vatha 
disease is 
more 
prevalent in 
Neidhal land 
 
 
PITHAM 
 
 
Kaar kalam 
 
 
Koothir kalam 
 
 
Munpani 
Pitha disease 
is more 
prevalent in 
Mullai land 
 
 
KAPHAM 
 
 
Pinpani 
 
 
Elavenil kalam 
 
 
Mudhuvenil 
kalam 
Kaphadisease 
is more 
prevalent in  
Kurunchi 
land 
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UDAL VANMAI (IMMUNITY): 
            Siddhars classify Udal vanmai as three types. They are 
1. Iyarkai vanmai 
2. Kala vanmai 
3. Seyarkai vanmai 
 
                        Since VATHA KARSANAM patients are suffering with pain as 
principal symptom, we came to understand that it is because of alteration in Vali 
thathu and Vali should be the primary causative factor (Muthanmai kutram). It can be 
confirmed by the words of great Siddhar Therayer 
                       “Å¡¾ÁÄ¡Ð §ÁÉ¢ ¦¸¼Ð” 
 
PINIYARI MURAIMAI (DIAGNOSIS): 
           It means the method of diagnosing the disease.           
‘kjpj;jplw;fUik tha;e;j 
khz;gupfhunky;yhe; 
                  Jjpj;jpl Tzu;e;jhNdDe; 
      Jfswg; gzpapd;wd;ik 
              gjpj;jpl Tzuhdhfpw; 
gaDwhdhfhyhNd 
             tpjpj;jpL gpzpj;jpwj;ij 
       tpsk;GJ Kjw;fz;kd;Ndh” 
- rpfpr;rh uj;jpdjPgk;- gf;fk; 3 
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              The above poem describes that diagnosis is very important for the physician to 
treat the disease. 
Four steps are followed in diagnosing the disease. They are, 
a. Poriyaal arithal 
b. Pulanal therthal 
c. Vinaathal  
d. Envagaithervu  
In detail, 
 
a. Poriyaal arithal: 
                     In this the physician should carefully observe the changes that occur in 
the five sensory organs (Porigal) of the patient. 
 
b.Pulanal therthal: 
                 The physician carefully applies his five senses of perception, smell, taste, 
vision, touch and sound to understand the condition of the patient. 
c.Vinaathal: 
                 The physician should interrogate about the patients name, age, occupation, 
socio economic status, food habits, history of past illness, history of present illness, 
family history, diabetic history and frequency of symptoms. 
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d.ENVAGAI THERVUKAL 
‘eh epwk; nkhop tpop ky%j;jpuk; 
ehb guprkpit kUj;JtuhAjk;” 
-Neha;ehly; Neha; Kjdhly;-253 
ehbahy;  Kd;Ndhu;nrhd;d 
ey;nyhypguprj;jhYk;  
           
ePba tpopapdhYk; epd;w 
ehf;Fwpg;gpdhYk; 
         
thba NkdpahYk; kynkhL ePupdhYk; #ba 
tpahjpjd;idr; RfKld;mwpe;JghNu” 
 
- jpUke;jpuk; -10 jpUkiw 
 
                             Nowadays advanced diagnostic tools have been developed by 
modern bio-medical scientists. But Siddhars have given eight diagnostic 
methodological tools. They are called as Envagai thervu. 
Eight fold system of clinical assessments 
Siddhars have given eight diagnostic methodological tools. They are, 
1. Naa 
2. Niram 
3. Mozhi 
4. Vizhi 
5. Malam 
6. Moothiram 
7. Naadi 
8. Parisam 
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GENERAL FINDINGS: 
1. NAA: 
i. Signs and symptoms in the tongue are noted here. 
ii. Color, salivary secretion, ulcers, coating, inflammation, taste 
changes, deviation and its nature are generally noted. 
 
       In VATHA KARSANAM the naa may be affected due to the pallor of the 
tongue and dryness of mouth due to polyuria. 
 
2. NIRAM: 
i. The color of the skin is noted here. 
 
          In VATHA KARSANAM the niram may be affected due to the pallor of the 
body and sometimes hyper pigmentation of body. 
3.  MOZHI: 
ii. Character of the speech is noted, mainly uratha olli(high pitched), 
thazhntha olli(low pitched), or resembles the sound of any 
instrument. 
 
In VATHA KARSANAM the mozhi will be affected to the patients who have 
severe pain leading to the thazhntha olli 
4. VIZHI: 
iii. Character of the eye is noted. Color, warm, burning sensation, 
irritation, visual Perception.   
     In VATHA KARSANAM the vizhi may be affected due to the pallor of the 
lower eyelid, vision disturbances’ like phrespiobhia, cataract (bilateral& 
unilateral). 
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5. MALAM: 
iv. The stools are examined for quantity; hardening (malakattu), 
loose motion (bethi), Color and smell. 
 
   In VATHA KARSANAM the malam will be affected due to either constipation 
or diarrhea. 
    6. MOOTHIRAM: 
   a. Neerkuri: 
v. The urine is examined for its color, odour, volume, froth and 
weight. 
 In VATHA KARSANAM the moothiram will be affected due to polyuria, 
burning micturation, urgency of urine. 
 
b.NEIKURI 
‘mUe;J khwp ujKk; mtpNuhjkjha;  
  mf;fy; myu;jy;mfhyt+d; jtpu;jow; 
 Fw;wstUe;jp cwq;fp itfiw 
 Mbf;fyrj; jhtpNa fhJnga; 
 njhUK$u;j;jf; fiyf;Fl;gL ePupd; 
 epwf;Fwp nea;Fwp epUkpj;jy; flNd” 
          -rpj;j kUj;Jthq;fr; RUf;fk;  gf;fk;509  
                      
              The early morning urine of the patient is analyzed by dropping a drop of 
gingely oil on the surface of the urine sample. The accumulation, formations, changes, 
and dispersal under the sunlight without any external disturbances of the urine sample 
can be noted.  
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• Vatha neer - The oil spreads like snake 
• Pitha neer - The oil spreads like ring 
• Kapha neer - The oil spreads like pearl 
• If the oil spreads gradually, it indicates good prognosis 
• If the oil spreads fast or gets mixed completely with urine or sinks in urine, it 
suggests bad prognosis. 
 
Since VATHA KARSANAM  is due to the derangement of vatham and 
pitham,the neikuri will be vatha or pitha neer. 
7. NAADI: 
             Naadi is a Unique Siddha Pulse reading . 
À¢ò¾ò¾¢ø Å¡¾Á¡¸¢ø À¢¼¡¢Ôí¸¡Öí¨¸Ôí 
Ìò¾Ð §À¡§ÄÂ¡Ìõ.............................. 
«ò¾¢Â¡ÔÄÕ§ÁÉ¢................. 
                              -«¸ò¾¢Â ¿¡Ê 
 
 
 
º¡üÈÀ¢ò  ¾ò¾¢ø ºÐÃ¡¸ Å¡¾ÓÈ 
²üÈì ¸¡Ä ¨¸À¢¼¡¢ ±íÌ§Á 
ÌòÐí ...... Å¡ö §¸¡ÀÁ¢Ìõ ¸¡ÔÁÉø 
                              -¸ñÏº¡Á¢Âõ 
 
 
þÕÁ¢§Â Å¡¾Óõ À¢ò¾Óõ ÜÊø 
........... ¯ñ¼ ¯¼ø ¸¡ó¾¢Îõ 
............°§½¡Î ¯È¢ïº¢ þÉ¢ìÌõ 
§¿÷ó¾¢Î §Á¸õ ¯û¦Ç§¾¡ýÈ¢§Â ¦À¡Õó¾¢ ¦ÁöÂ¢ø 
                              - §¾Ãý ÁÕòÐÅ À¡Ã¾õ 
 
¯Ú¾¢ÔûÇ À¢ò¾ÁÐ §¾¡ýÈ¢ø ¦ÅôÒ 
ÅÇ÷§º¡¨¸ ÂÆ ¦Ä¡¢× ¸¡ó¾ø 
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                              - º¾¸ ¿¡Ê 
 
 
ÜÈ¢¼§Å À¢ò¾ÁÐ Á£È¢üÈ¡É¡ø 
¦¸¡Îí¸¡ó¾Ö¼ý..... 
........¿¡ÅÈðº¢ 
                             -«¸ò¾¢Â÷ ¿¡Ê 
 
 
¾¡ý ±ýÈ À¢ò¾ Á£È¢ø º¼õ ±øÄ¡í¸¡ó¾ø ¸¡Ïõ 
                             
                                - ¸¡Å¢Âò¾¢ý ¿¡Ê 
 
 
À¢ò¾ò¾¢ø À¢ò¾Á¡¸¢ø 
«¸ò¾¢Â¡ ÔÄÕ§ÁÉ¢ 
ÅüÈ¢§Â ¦ÅÙòÐì ¸¡Äõ 
               -«¸ò¾¢Â÷ ¿¡Ê 
 
 
¾¨ÆôÀ¡É À¢ò¾ò¾¢ÖðÊí ¦¸¡ñ¼¡ø 
......... ¦Â¡¢× ¾¡¸õ 
                                     - §¿¡ö ¿¡¼ø §¿¡ö Ó¾ø ¿¡¼ø 
 
 
 
LINE OF TREATMENT: 
 
1. Since VATHAKARSANAM is a Vatha disease, purgative is given to balance the 
Vatham. 
 
            ‘tpNurdj;jhy; thjk; jhOk;”;  
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  Agasthiyar kuzhambu  - 60 mgs early morning with chukka kudineer30ml. 
2.MEDICINE: 
KARUNGALI VER KUDINEER 30 ml twice a day (before food) 
3.DURATION OF TREATMENT: 
45 DAYS 
 
4.PATHIYAM AND APATHIYAM: 
DIET CHART & GENERAL FOOT CARE ADVICE 
 
ÁÐ§Á¸ ¯½× Ó¨È¸û: 
 
¸¡¨Ä 6.30    :       ¸¡À¢/ Ë/À¡ø ( º÷ì¸¨Ã þøÄ¡Áø) 
 
 
¸¡¨Ä 8.30   :        þðÄ¢/§¾¡¨º/þÊÂ¡ôÀõ/¦À¡í¸ø/ 
                              ¯ôÒÁ¡/ºôÀ¡¾¢/§¸úÅÃÌ Üú/º¡õÀ¡÷/ 
                              ºðÉ¢(§¾í¸¡ö ¾Å¢Ã)/ Óð¨¼ ¦Åû¨Ç ÁðÎõ.  
 
 
 
¸¡¨Ä 10.30  :        §Á¡÷/ ¸¡ö¸È¢ Ýô/ ¦ÅûÇ¡¢ ¸¡ö/¾ì¸¡Ç¢ Ýô 
 
 
 
 
Á¾¢Âõ 1.30     :        º¡¾õ/ ºôÀ¡¾¢/ À¢¦Ãªý ¦Ã¡ðÊ/ §¸úÅÃÌ¸Ä¢ 
                                º¡õÀ¡÷/ÀÕôÒ/ Á£ý/ ¸£¨Ã/¸¡ö¸È¢ ¦À¡È¢Âø/ 
                                 ¾Â¢÷/§Á¡÷ 
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Á¡¨Ä 4.00      :        ¸¡À¢/Ë/À¡ø 
                                 Íñ¼ø/À¢Š¸ð/º¡ýÅ¢Š/§¸¡Ð¨Á À¢Ãð. 
 
 
  
 þÃ× 7.30       :        ºôÀ¡ò¾¢/þðÄ¢/§¾¡¨º/þÊÂ¡ôÀõ/º¡õÀ¡÷/         
                                 ÀÕôÒ/§¸¡Æ¢/Á£ý/¸¡ö¸È¢/ 
                                 Ãºõ/§Á¡÷/¾Â¢÷/ÀÆõ 
 
 
 
þÃ× 9.30         :        À¡ø(º÷ì¸¨Ã þøÄ¡Áø) 
 
  GENERAL ADVICE:  
 Control the blood sugar level 
 Follow the diabetic diet advice 
 Follow the foot care advice 
  Do routine check up like nerve conduction study, Biothesimetry, mono filament 
test, HbA1C 
 Regular check up’s for renal function, eye fundus examination, liver function test 
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FOOT CARE ADVICE:  
• ¦ºöÂ §ÅñÊÂ¨Å: 
 
               1.ÁÕòÐÅ¨Ã ¯¡¢Â ¸¡Ä þ¨¼¦ÅÇ¢¸Ç¢ø ºó¾¢òÐ ¸¡ø¸Ç¢ý 
À¡¢§º¡¾¨É¸¨Ç §Áü¦¸¡ûÇ §ÅñÎõ. 
 
               2.¸¡ø¸¨Ç Íò¾Á¡¸ ¸ØÅ §ÅñÎõ.«Åü¨È ¿ýÈ¡¸ ¯Ä÷ò¾ §ÅñÎõ. 
 
               3.À¡¾í¸Ç¢ø ¦ÅÊôÒ¸û,¦¸¡ôÒÇí¸û,¿¢È                 Á¡ÚÀ¡Î¸û,Å£ì¸õ 
²§¾Ïõ ¯ûÇÉÅ¡ ±É «Êì¸Ê À¡¢§º¡¾¢ì¸×õ. 
           4.ÌÇ¢ìÌõ ¾ñ½£¡¢ý ¦ÅôÀ ¿¢¨Ä¨Â ¨¸     ãðÊ¨Éì  ¦¸¡ñÎ 
À¡¢§º¡¾¢ì¸×õ. 
              5.¸¡ø¸¨Ç ±ô§À¡Ðõ ®ÃôÀ¨ºÔ¼ý ¨ÅòÐì¦¸¡ûÇ×õ. 
              6.¦À¡Õò¾Á¡Éì ¸¡Ä½¢¸¨Ç ÀÂýÀÎò¾×õ.  
 
• ¦ºöÂìÜ¼¡¾¨Å:  
            1.¦À¡Õó¾¡¾ ¸¡Ä½¢¸¨Ç «½¢¾ø Ü¼¡Ð.  
 
             2. À¡¾í¸¨Ç ¿£ñ¼ §¿Ãõ ¾ñ½£¡¢ø  ãú¸ ¨Åò¾ø Ü¼¡Ð 
 
           3.¦ÅüÚì ¸¡ø¸Ç¢ø ¿¼ò¾ø Ü¼¡Ð. 
 
           4.¸¡ø¸Ç¢ø ²§¾Ïõ ¦¸¡ôÒÇõ þÕôÀ¢ý «¨¾ ¯¨¼ò¾ø Ü¼¡Ð 
           5.«¾¢¸ ¦ÅôÀÁ¡É þ¼í¸Ç¢ø «ÁÕ¾ø Ü¼¡Ð. 
 
       6.Ü÷¨ÁÂ¡É ¦À¡Õð¸Ç¡ø ¿¸ò¨¾ ¿ÕìÌ¾ø Ü¼¡Ð. 
 
       7.¸¡Ä¡½¢ ÁüÚõ ¾Êò¾ §¾¡ø þÅü¨È ¾¡í¸Ç¡¸§Å ¿£ìÌ¾ø Ü¼¡Ð. 
 
       8. Ò¨¸ôÀ¢Êò¾¨Äò ¾Å¢÷ì¸×õ.²¦ÉÉ¢ø Ò¨¸ À¢Êò¾ø ¸¡ø¸ÙìÌ 
¦ºøÖõ  þÃò¾ µð¼ò¨¾ Ì¨ÈìÌõ. 
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        YOGA 
• Yoga practice 
                  Yogic Physical exercise makes the muscles healthy and strong. It also 
tones up   all the involuntary organs of the body which are concerned with the 
processes as digestion, evacation, circulation, respiration and secretion and through 
them, the autonomic nervous system which regulates their activities. 
-Yogic Aganas for health & Vigour. 
Pranayanam (breathing excersice)  
 Breathing is regulated with inspiration, expiration and retention of air in the 
ratio of 1 : 2 : 4 
 On practicing pranayamam regularly, supply adequate oxygen to nerves cells. 
The cells of the brain and spinal cord consume much more oxygen. It makes the mind 
alert and improves concentration. 
V.G. Rali  
Specific Asanas for Diabetes – Dhanurasana  
 
 
Dhanurasana (bow pose) 
 Lie flat on the Abdomen with the legs and feet together and the arms and 
hands beside  the body. 
 Bend the knees and bring the heels close to the buttocks. 
 Clasp the hands around the ankles. 
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 Place the chin on the floor. 
 This is the starting position. 
 Tightens the leg muscles and push the feet away from the body. Arch the 
back, lifting the thighs, chest and head together. 
 Keep the arms straight. 
 In the final position the head is tilted back and the abdomen supports the entire 
body on the floor. The only muscular contraction is in the  legs; the back and 
arms remain relaxed. 
 Hold the final position for as long as it is comfortable and then slowly relaxing 
the leg muscles, lower the legs, chest and head to the starting position  
 Release the pose and relax in the prone position until the respiration returns to 
normal. 
 Benefits : The pancreas and adrenal glands are toned balancing the secretions. 
It is recommended in Yoga therapy for diabetes. 
 Pachimottanasana (back stretching pose) 
 
 Sit on the floor with the legs outstretched, feet together and hands on the 
knees. 
 This is the starting position. 
 Relax the whole body 
 Slowly bend forward from the hips, sliding the hands down the legs. Try to 
grasp the big toes with the fingers and thumbs. If this is impossible, hold the 
heels, ankles or any part of the legs that can be reached comfortably. 
 Move slowly without forcing or jerking. 
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 Hold the position for a few seconds. Relax the back and leg muscles allowing 
them to gently stretch. 
 Keeping the legs straight and utilizing the arm muscles, not the back muscles, 
begin to bend the elbows and gently bring the trunk down towards the legs, 
maintaining a firm grip on the toes, feet or legs. 
 Try to touch the knees with the forehead. Do not strain. 
 This is the final position. 
 Hold the position for as long as is comfortable and relax. 
 Slowly return to the starting position. 
 Benefits : It tones and massages the entire abdominal and pelvic region 
including the liver, pancrease, Spleen, Kidneys and adrenal glands.   
 Ardha  Matsyendrasana (half spinal twist)  
 Sit with the legs stretched out in front of the body. 
 Bend the right leg and place the right foot flat on the foot on the outside of the 
left knee. 
 The toes of the right foot should face forward.  
 Bend the left leg and bring the foot around to the right buttock. The outside 
edge of the foot should be in contact with floor. 
 Pass the left arm through the space between the chest and the right knee, and 
place it agains the outside of the right leg. 
 Hold the right foot or ankle with the left hand, so that the right knee is close to 
the left armpit. 
 Sit up as straight as possible. 
 Raise the right arm in front of the body and gaze at the fingertips.  
 Slowly twist to the right, simultaneously moving the arm, trunk and head. 
 Use the left arm as a lever against the right leg to twist the trunk as far as 
possible without using the back muscles. 
 Follow the tips of the fingers of the right hand with the gaze and look over the 
right shoulder. 
 Do not strain the back. 
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 Bend the right elbow and place the arm around the back of the waist. The back 
of the right hand should wrap around the left side of the waist. 
 Alternatively, it can be placed as high as possible between the shoulder blades 
with the fingers pointing up. This arm position enforces the straightness of the 
spine.  
 Reverse the movements to come out of the posture and repeat on the other 
side.  
 Halasana (plough pose) 
 
 Lie flat on the back with the legs and feet together. Place the arms beside the 
body with the palms facing down.  
 Relax the whole body. 
 Raise both legs to the vertical position, keeping them straight and together, 
using only the abdominal muscles. 
 Press down on the arms and lift the buttocks, rolling the back away from the 
floor. Lower the legs over the head. 
 Do not force the toes to touch the floor. 
 Turn the palms up, bend the elbows and place the hands behind the ribcage to 
support the back as in sarvangasana.  
 Relax and hold the final pose for as long as is comfortable. 
 Return to the starting position by lowering the arms with the plams facing 
down, then slowly lower the back and buttocks to the floor.  
 Raise the legs to the vertical position. Using the abdominal muscles, lower the 
legs to the starting position, keeping the knees straight 
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 Benefits : It promotes the production of insulin by the pancreas. It boosts the 
immune system.  
 General Asanas : 
 Surya Namaskara  
 Savasana  
 Theraiyar clearly explains mild sunrays are much beneficial to our body to 
prevent diseases.  
Savasanam 
• By doing savasanam, the whole body is relaxed and rejunuvate the body.  
• This Asana being practiced in the world for relaxation techniques. 
• Effect of Yoga Asanas on nerve conduction in Type II Diabetes.  
• Yoga asanas included “Suryanamskar, Konasan, Padmasan pranayam,  
 
Paschimottansan, Ardhmatsyendrasan, Shavasan. The yoga exercises were 
performed for 30-40 minutes every day 40 days in above sequence. The subjects were 
prescribed certain medicines and diet. 
 
Yoga asanas have a beneficial effect on glycaemic control and improve nerve 
function in mild to moderate type II diabetes with such clinical neuropathy. 
-Indian Journal physiology & Pharmacology 2002 : 46 (3)  
                                                                                       Varun Malhotra etal 
 
Stress Management 
                                 
                        Diagnosis of diabetes mellitus is a stressful situation in life of an 
individual and appropriate management requires a holistic approach that includes 
behavioral modification to develop positive attitude and healthy life style. A 
satisfactory treatment plan should include special attention to person with diabetes, 
quality of life, coping skills, optimal family support and a healthy workplace 
environment. Appropriate support and counseling is an essential component of the 
management at the time of diagnosis and throughout life. 
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6. PREVENTION: 
•  Balanced diet 
• Regular exercise 
• Suriya namesakar 
• Oil bath twice in a week 
• Avoid Junk foods & sweets 
• Avoid tobacco 
• Avoid Contraceptives 
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MODERN ASPECT 
The Neuron 
Neurons 
 
It is clear that most of what we think of as our mental life involves the activities of the 
nervous system, especially the brain.  This nervous system is composed of billions of 
cells, the most essential 
being the nerve cells or 
neurons.  There are 
estimated to be as many as 
100 billion neurons in our 
nervous systemspinal cord 
neuron 
 
 
A typical neuron has all the parts that any cell would have, and a few specialized 
structures that set it apart.  The main portion of the cell is called the soma or cell 
body.  It contains the nucleus, which in turn contains the genetic material in the form 
of chromosomes. 
          Neurons have a large number of extensions called dendrites.  They often look 
likes branches or spikes extending out from the cell body.  It is primarily the surfaces 
of the dendrites that receive chemical messages from other neurons. 
 
       One extension is 
different from all the others, 
and is called the axon.  
Although in some neurons, it 
is hard to distinguish from 
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the dendrites, in others it is easily distinguished by its length.  The purpose of the axon 
is to transmit an electro-chemical signal to other neurons, sometimes over a 
considerable distance.  In the neurons that make up the nerves running from the spinal 
cord to your toes, the axons can be as long as three feet.   
 
                   Longer axons are usually covered with a myelin sheath, a series of fatty 
cells which have wrapped around an axon many times.  These make the axon look like 
a necklace of sausage-shaped beads.  They serve a similar function as the insulation 
around electrical wire. 
 
                At the very end of the axon is the axon ending, which goes by a variety of 
names such as the bouton, the synaptic knob, the axon foot, and so on   It is there that 
the electro-chemical signal that has travelled the length of the axon is converted into a 
chemical message that travels 
to the next neuron. 
axon endings 
 
         Between the axon ending 
and the dendrite of the next 
neuron is a very tiny gap 
called the synapse (or 
synaptic gap, or synaptic 
cleft), which we will discuss 
in a little bit.  For every neuron, there are between 1000 and 10,000 synapses. 
      When chemicals contact the surface of a neuron, they change the balance of ions 
(electrically charged atoms) between the inside and outside of the cell membrane.  
When this change reaches a threshold level, this effect runs across the cell's membrane 
to the axon.  When it reaches the axon, it initiates the action potential, which is a 
rapidly moving exchange of ions. 
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The surface of the axon contains hundreds of thousands of miniscule mechanisms 
called ion channels. When the charge enters the axon, the ion channels at the base of 
the axon allow positively charged ions to enter the axon, changing the electrical 
balance between inside and outside.  This causes the next group of ion channels to do 
the same, while other channels return positive ions to the outside, and so on all the 
way down the axon. 
 
 
             In this little diagram, the red represents the positive ions going into the axon, 
while the orange represents positive ions going out.  The action potential travels at a 
rate of 1.2 to 250 miles per hour 
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The synapse: 
 
                     When the action potential reaches the axon ending, it causes tiny bubbles 
of chemicals called vesicles to release their contents into the synaptic gap.  These 
chemicals are called neurotransmitters.  These sail across the gap to the next neuron, 
where they find special places on the cell membrane of the next neuron called 
receptor sites. 
 
 
 
 
The neurotransmitter acts like a little key, and the receptor site like a little lock.  When 
they meet, they open a passage way for ions, which then change the balance of ions on 
the outside and the inside of the next neuron.  And the whole process starts all over 
again. 
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              While most neurotransmitters are excitatory -- i.e. they excite the next 
neuron -- there are also inhibitory neurotransmitters.  These make it more difficult for 
the excitatory neurotransmitters to have their effect. 
 
 
 
Types of Neurons (Nerve Cells) 
               While there are many different kinds of neurons, there are three broad 
categories based on function: 
 
1.  Sensory neurons are sensitive to various non-neural stimuli.  There are sensory 
neurons in the skin, muscles, joints, and organs that indicate pressure, temperature, 
and pain.  There are more specialized neurons in the nose and tongue that are sensitive 
to the molecular shapes we perceive as tastes and smells.  Neurons in the inner ear are 
sensitive to vibration, and provide us with information about sound.  And the rods and 
cones of the retina are sensitive to light, and allow us to see. 
 
2.  Motor neurons are able to stimulate muscle cells throughout the body, including 
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the muscles of the heart, diaphragm, intestines, bladder, and glands. 
 
3.  Interneurons are the neurons that provide connections between sensory and motor 
neurons, as well as between themselves.  The neurons of the central nervous system, 
including the brain, are all interneurons. 
 
Most neurons are collected into "packages" of one sort or another, sometimes visible 
to the naked eye.  A clump of neuron cell bodies, for example, is called a ganglion 
(plural: ganglia) or a nucleus (plural: nuclei).  A fiber made up of many axons is 
called a nerve.  In the brain and spinal cord, areas that are mostly axons are called 
white matter, and it is possible to differentiate pathways or tracts of these axons.  
Areas that include large number of cell bodies are called gray matter. 
One way to classify neurons is by the number of extensions that extend from the 
neuron's cell body (soma). 
 
Bipolar neurons have two processes extending from the cell body (examples: retinal 
cells, olfactory epithelium cells). 
 
Pseudounipolar cells (example: dorsal root ganglion cells). Actually, these cells have 
2 axons rather than an axon and dendrite. One axon extends centrally toward the 
spinal cord, the other axon extends toward the skin or muscle. 
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Multipolar neurons have many processes that extend from the cell body. However, 
each neuron has only one axon (examples: spinal motor neurons, pyramidal neurons, 
Purkinje cells). 
Neurons can also be classified by the direction that they send information. 
• Sensory (or afferent) neurons: send information from sensory receptors (e.g., 
in skin, eyes, nose, tongue, ears) TOWARD the central nervous system. 
• Motor (or efferent) neurons: send information AWAY from the central 
nervous system to muscles or glands. 
• Interneurons: send information between sensory neurons and motor neurons. 
Most interneurons are located in the central nervous system. 
The Sympathetic Nerves 
The sympathetic nervous system innervates all the smooth muscles and the various 
glands of the body, and the striated muscle of the heart. The efferent sympathetic 
fibers which leave the central nervous system in connection with certain of the cranial 
and spinal nerves all end in sympathetic ganglia and are known as preganglionic 
fibers. From these ganglia postganglionic fibers arise and conduct impulses to the 
different organs. In addition, afferent or sensory fibers connect many of these 
structures with the central nervous system. 
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The right sympathetic chain and its connections with the thoracic, abdominal, 
and pelvic plexuses. (After Schwalbe.)  
  
            The peripheral portion of the sympathetic nervous system is characterized by 
the presence of numerous ganglia and complicated plexuses. These ganglia are 
connected with the central nervous system by three groups of sympathetic efferent or 
preganglionic fibers, i. e., the cranial, the thoracolumbar, and the sacral. These 
outflows of sympathetic fibers are separated by intervals where no connections exist. 
The cranial and sacral sympathetics are often grouped together owing to the 
resemblance between the reactions produced by stimulating them and by the effects of 
certain drugs. Acetyl-choline, for example, when injected intravenously in very small 
doses, produces the same effect as the stimulation of the cranial or sacral 
sympathetics, while the introduction of adrenalin produces the same effect as the 
stimulation of the thoracolumbar sympathetics. Much of our present knowledge of the 
sympathetic nervous system has been acquired through the application of various 
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drugs, especially nicotine which paralyzes the connections or synapses between the 
preganglionic and postganglionic fibers of the sympathetic nerves. When it is injected 
into the general circulation all such synapses are paralyzed; when it is applied locally 
on a ganglion only the synapses occurring in that particular ganglion are paralyzed. 
  Langley,  who has contributed greatly to our knowledge, adopted a terminology 
somewhat different from that used here and still different from that used by the 
pharmacologists. This has led to considerable confusion, as shown by the arrangement 
of the terms in the following columns. Gaskell has used the term involuntary nervous 
system.  
Gray. Langley. Meyer and Gottlieb.  
Sympathetic nervous system. 
Autonomic nervous 
system. 
Vegetative nervous 
system. 
Cranio-sacral sympathetics. Parasympathetics. Autonomic. 
Oculomotor sympathetics. Tectal autonomics. Cranial autonomics. 
Facial Fsympathetics. 
Bulbar autonomics. 
 
Glossopharyngeal 
sympathetics.  
Vagal sympathetics. 
 
Sacral sympathetics. Sacral autonomics. Sacral autonomics. 
Thoracolumbar sympathetics. Sympathetic. Sympathetic. 
 
Thoracic autonomic. 
 
Enteric. Enteric. Enteric. 
 
  
The Cranial Sympathetics: 
                                  The cranial sympathetics include sympathetic efferent fibers in 
the oculomotor, facial, glossopharyngeal and vagus nerves, as well as sympathetic 
afferent in the last three nerves. 
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  The Sympathetic Efferent Fibers of the Oculomotor Nerve probably arise from 
cells in the anterior part of the oculomotor nucleus which is located in the tegmentum 
of the mid-brain. These preganglionic fibers run with the third nerve into the orbit and 
pass to the ciliary ganglion where they terminate by forming synapses with 
sympathetic motor neurons whose axons, postganglionic fibers, proceed as the short 
ciliary nerves to the eyeball. Here they supply motor fibers to the Ciliaris muscle and 
the Sphincter pupillæ muscle. So far as known there are no sympathetic afferent fibers 
connected with the nerve. 
                                The Sympathetic Efferent Fibers of the Facial Nerve are 
supposed to arise from the small cells of the facial nucleus. According to some authors 
the fibers to the salivary glands arise from a special nucleus, the superior salivatory 
nucleus, consisting of cells scattered in the reticular formation, dorso-medial to the 
facial nucleus. These preganglionic fibers are distributed partly through the chorda 
tympani and lingual nerves to the submaxillary ganglion where they terminate about 
the cell bodies of neurons whose axons as postganglionic fibers conduct secretory and 
vasodilotar impulses to the submaxillary and sublingual glands. Other preganglionic 
fibers of the facial nerve pass via the great superficial petrosal nerve to the 
sphenopalatine ganglion where they form synapses with neurons whose 
postganglionic fibers are distributed with the superior maxillary nerve as vasodilator 
and secretory fibers to the mucous membrane of the nose, soft palate, tonsils, uvula, 
roof of the mouth, upper lips and gums, parotid and orbital glands. 
                                    There are supposed to be a few sympathetic afferent fibers 
connected with the facial nerve, whose cell bodies lie in the geniculate ganglion, but 
very little is known about them. 
                                     The Sympathetic Afferent Fibers of the Glossopharyngeal 
Nerve are supposed to arise either in the dorsal nucleus (nucleus ala cinerea) or in a 
distinct nucleus, the inferior salivatory nucleus, situated near the dorsal nucleus. These 
preganglionic fibers pass into the tympanic branch of the glossopharyngeal and then 
with the small superficial petrosal nerve to the otic ganglion. Postganglionic fibers, 
vasodilator and secretory fibers, are distributed to the parotid gland, to the mucous 
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membrane and its glands on the tongue, the floor of the mouth, and the lower gums. 
                                     Sympathetic Afferent Fibers, whose cells of origin lie in the 
superior or inferior ganglion of the trunk, are supposed to terminate in the dorsal 
nucleus. Very little is known of the peripheral distribution of these fibers. 
                                    The Sympathetic Efferent Fibers of the Vagus Nerve are 
supposed to arise in the dorsal nucleus (nucleus ala cinerea). These preganglionic 
fibers are all supposed to end in sympathetic ganglia situated in or near the organs 
supplied by the vagus sympathetics. The inhibitory fibers to the heart probably 
terminate in the small ganglia of the heart wall especially the atrium, from which 
inhibitory postganglionic fibers are distributed to the musculature. The preganglionic 
motor fibers to the esophagus, the stomach, the small intestine, and the greater part of 
the large intestine are supposed to terminate in the plexuses of Auerbach, from which 
postganglionic fibers are distributed to the smooth muscles of these organs. Other 
fibers pass to the smooth muscles of the bronchial tree and to the gall-bladder and its 
ducts. In addition the vagus is believed to contain secretory fibers to the stomach and 
pancreas. It probably contains many other efferent fibers than those enumerated 
above. 
  
                                  Sympathetic Afferent Fibers of the Vagus, whose cells of 
origin lie in the jugular ganglion or the ganglion nodosum, probably terminate in the 
dorsal nucleus of the medulla oblongata or according to some authors in the nucleus of 
the tractus solitarius. Peripherally the fibers are supposed to be distributed to the 
various organs supplied by the sympathetic efferent fibers. 
The Sacral Sympathetics 
                                The Sacral Sympathetic Efferent Fibers leave the spinal cord 
with the anterior roots of the second, third and fourth sacral nerves. These small 
medullated preganglionic fibers are collected together in the pelvis into the nervus 
erigentes or pelvic nerve which proceeds to the hypogastric or pelvic plexuses from 
which postganglionic fibers are distributed to the pelvic viscera. Motor fibers pass to 
the smooth muscle of the descending colon, rectum, anus and bladder. Vasodilators 
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are distributed to these organs and to the external genitalia, while inhibitory fibers 
probably pass to the smooth muscles of the external genitalia. Afferent sympathetic 
fibers conduct impulses from the pelvic viscera to the second, third and fourth sacral 
nerves. Their cells of origin lie in the spinal ganglia. 
  
The Thoracolumbar Sympathetics: 
                      
                               The thoracolumbar sympathetic fibers arise from the dorso-
lateral region of the anterior column of the gray matter of the spinal cord and pass 
with the anterior roots of all the thoracic and the upper two or three lumbar spinal 
nerves. These preganglionic fibers enter the white rami communicantes and proceed to 
the sympathetic trunk where many of them end in its ganglia, others pass to the 
prevertebral plexuses and terminate in its collateral ganglia. The postganglionic fibers 
have a wide distribution. The vasoconstrictor fibers to the bloodvessels of the skin of 
the trunk and limbs, for example, leave the spinal cord as preganglionic fibers in all 
the thoracic and the upper two or three lumbar spinal nerves and terminate in the 
ganglia of the sympathetic trunk, either in the ganglion directly connected with its 
ramus or in neighboring ganglia. Postganglionic fibers arise in these ganglia, pass 
through gray rami communicantes to all the spinal nerves, and are distributed with 
their cutaneous branches, ultimately leaving these branches to join the small arteries. 
The postganglionic fibers do not necessarily return to the same spinal nerves which 
contain the corresponding preganglionic fibers. The vasoconstrictor fibers to the head 
come from the upper thoracic nerves, the preganglionic fibers end in the superior 
cervical ganglion. The postganglionic fibers pass through the internal carotid nerve 
and branch from it to join the sensory branches of the various cranial nerves, 
especially the trigeminal nerve; other fibers to the deep structures and the salivary 
glands probably accompany the arteries. 
        
                        The postganglionic vasoconstrictor fibers to the bloodvessels of the 
abdominal viscera arise in the prevertebral or collateral ganglia in which terminate 
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many preganglionic fibers. Vasoconstrictor fibers to the pelvic viscera arise from the 
inferior mesenteric ganglia. 
                      The pilomotor fibers to the hairs and the motor fibers to the sweat glands 
apparently have a distribution similar to that of the vasoconstrictors of the skin. 
                        A vasoconstrictor center has been located by the physiologists in the 
neighborhood of the facial nucleus. Axons from its cells are supposed to descend in 
the spinal cord to terminate about cell bodies of the preganglionic fibers located in the 
dorsolateral portion of the anterior column of the thoracic and upper lumbar region. 
                        The motor supply to the dilator pupillæ muscle of the eye comes from 
preganglionic sympathetic fibers which leave the spinal cord with the anterior roots of 
the upper thoracic nerves. These fibers pass to the sympathetic trunk through the white 
rami communicantes and terminate in the superior cervical ganglion. Postganglionic 
fibers from the superior cervical ganglion pass through the internal carotid nerve and 
the ophthalmic division of the trigeminal nerve to the orbit where the long ciliary 
nerves conduct the impulses to the eyeball and the dilator pupillæ muscle. The cell 
bodies of these preganglionic fibers are connected with fibers which descend from the 
mid-brain. 
  Other postganglionic fibers from the superior cervical ganglion are distributed as 
secretory fibers to the salivary glands, the lacrimal glands and to the small glands of 
the mucous membrane of the nose, mouth and pharynx. 
  The thoracic sympathetics supply accelerator nerves to the heart. They are supposed 
to emerge from the spinal cord in the anterior roots of the upper four or five thoracic 
nerves and pass with the white rami to the first thoracic ganglion, here some 
terminate, others pass in the ansa subclavia to the inferior cervical ganglion. The 
postganglionic fibers pass from these ganglia partly through the ansa subclavia to the 
heart, on their way they intermingle with sympathetic fibers from the vagus to form 
the cardiac plexus. 
  Inhibitory fibers to the smooth musculature of the stomach, the small intestine and 
most of the large intestine are supposed to emerge in the anterior roots of the lower 
thoracic and upper lumbar nerves. These fibers pass through the white rami and 
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sympathetic trunk and are conveyed by the splanchnic nerves to the prevertebral 
plexus where they terminate in the collateral ganglia. From the celiac and superior 
mesenteric ganglia postganglionic fibers (inhibitory) are distributed to the stomach, 
the small intestine and most of the large intestine. Inhibitory fibers to the descending 
colon, the rectum and Internal sphincter ani are probably postganglionic fibers from 
the inferior mesenteric ganglion. 
  The thoracolumbar sympathetics are characterized by the presence of numerous 
ganglia which may be divided into two groups,central and collateral. 
  The central ganglia are arranged in two vertical rows, one on either side of the 
middle line, situated partly in front and partly at the sides of the vertebral column. 
Each ganglion is joined by intervening nervous cords to adjacent ganglia so that two 
chains, thesympathetic trunks, are formed. The collateral ganglia are found in 
connection with three great prevertebral plexuses,placed within the thorax, abdomen, 
and pelvis respectively. 
  The sympathetic trunks (truncus sympathicus; gangliated cord) extend from the 
base of the skull to the coccyx. The cephalic end of each is continued upward through 
the carotid canal into the skull, and forms a plexus on the internal carotid artery; the 
caudal ends of the trunks converge and end in a single ganglion, the ganglion 
impar, placed in front of the coccyx. The ganglia of each trunk are distinguished 
as cervical, thoracic, lumbar, and sacral and, except in the neck, they closely 
correspond in number to the vertebræ. They are arranged thus: 
Cervical portion 
 
3 ganglia 
Thoracic portion 
 
12 ganglia 
Lumbar portion 
 
4 ganglia 
Sacral portion 
 
4 or 5 ganglia 
 
  In the neck the ganglia lie in front of the transverse processes of the vertebræ; in the 
thoracic region in front of the heads of the ribs; in the lumbar region on the sides of 
the vertebral bodies; and in the sacral region in front of the sacrum. 
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Connections with the Spinal Nerves.—Communications are established between the 
sympathetic and spinal nerves through what are known as the gray and white rami 
communicantes the gray rami convey sympathetic fibers into the spinal nerves and 
the white rami transmit spinal fibers into the sympathetic. Each spinal nerve receives a 
gray ramus communicans from the sympathetic trunk, but white rami are not supplied 
by all the spinal nerves. White rami are derived from the first thoracic to the first 
lumbar nerves inclusive, while the visceral branches which run from the second, third, 
and fourth sacral nerves directly to the pelvic plexuses of the sympathetic belong to 
this category. The fibers which reach the sympathetic through the white rami 
communicantes are medullated; those which spring from the cells of the sympathetic 
ganglia are almost entirely non-medullated. . 
            The three great gangliated plexuses (collateral ganglia) are situated in front 
of the vertebral column in the thoracic, abdominal, and pelvic regions, and are named, 
respectively, the cardiac, the solar or epigastric, and the hypogastric plexuses. They 
consist of collections of nerves and ganglia; the nerves being derived from the 
sympathetic trunks and from the cerebrospinal nerves. They distribute branches to the 
viscera. 
 
DIABETIC NEUROPATHY 
                                           Diabetic neuropathies are a family of nerve disorders 
caused by diabetes. People with diabetes can, over time, develop nerve damage 
throughout the body. Some people with nerve damage have no symptoms. Others may 
have symptoms such as pain, tingling, or numbness-loss of feeling-in the hands, arms, 
feet, and legs. Nerve problems can occur in every organ system, including the 
digestive tract, heart, and sex organs. 
                     About 60 to 70 percent of people with diabetes have some form of 
neuropathy. People with diabetes can develop nerve problems at any time, but 
risk rises with age and longer duration of diabetes. The highest rates of 
neuropathy are among people who have had diabetes for at least 25 years. 
Diabetic neuropathies also appear to be more common in people who have 
problems controlling their blood glucose, also called blood sugar. 
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Epidemiology 
A large American study estimated that 47% of patients with diabetes have some 
peripheral neuropathy. Neuropathy is estimated to be present in 7.5% of patients at the 
time of diabetes diagnosis. More than half of cases are distal symmetric 
polyneuropathy. Focal syndromes such as carpal tunnel syndrome (14-30%) 
radiculopathies/plexopathies, and cranial neuropathies account for the rest. Solid 
prevalence data for the latter 2 less-common syndromes is lacking. 
The wide variability in symmetric diabetic polyneuropathy prevalence data is due to 
lack of consistent criteria for diagnosis, variable methods of selecting patients for 
study, and differing assessment techniques. In addition, because many patients with 
diabetic polyneuropathy are initially asymptomatic, detection is extremely dependent 
on careful neurologic examination by the primary care clinician. The use of additional 
diagnostic techniques, such as autonomic or quantitative sensory testing, might result 
in a higher recorded prevalence. 
International statistics 
In a cohort of 4400 Belgian patients, Pirart et al found that 7.5% of patients already 
had neuropathy when diagnosed with diabetes. After 25 years, the number with 
neuropathy rose to 45%. In the United Kingdom, the prevalence of diabetic 
neuropathy among the hospital clinic population was noted to be around 29%. 
Diabetic neuropathy in racial minorities 
No definite racial predilection has been demonstrated for diabetic neuropathy. 
However, members of minority groups (eg, Hispanics, African Americans) have more 
secondary complications from diabetic neuropathy, such as lower-extremity 
amputations, than whites. They also have more hospitalizations for neuropathic 
complications. 
Sex differences in diabetic neuropathy 
DM affects men and women with equal frequency. However, male patients with type 
2 diabetes may develop diabetic polyneuropathy earlier than female patients, and 
neuropathic pain causes more morbidity in females than in males. 
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Diabetic neuropathy and advancing age 
Diabetic neuropathy can occur at any age but is more common with increasing 
age and severity and duration of diabetes 
Etiology 
Risk factors that are associated with more severe symptoms include the following 
• Poor glycemic control 
• Advanced age 
• Hypertension 
• Long duration of DM 
• Dyslipidemia 
• Smoking 
• Heavy alcohol intake 
• HLA-DR3/4 phenotype 
• Tall height 
Development of symptoms depends on many factors, such as total hyperglycemic 
exposure and other risk factors such as elevated lipids, blood pressure, smoking, 
increased height, and high exposure to other potentially neurotoxic agents such as 
ethanol. Genetic factors may also play a role 
Peripheral neuropathies have been described in patients with primary DM (types 1 and 
2) and in those with secondary diabetes of diverse causes, suggesting a common 
etiologic mechanism based on chronic hyperglycemia. The contribution of 
hyperglycemia has received strong support from the Diabetes Control and 
Complications Trial (DCCT). 
 
SYMPTOMS: 
 
                             Symptoms depend on the type of neuropathy and which nerves are 
affected. Some people with nerve damage have no symptoms at all. For others, the 
first symptom is often numbness, tingling, or pain in the feet. Symptoms are often 
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minor at first, and because most nerve damage occurs over several years, mild cases 
may go unnoticed for a long time. Symptoms can involve the sensory, motor, and 
autonomic-or involuntary-nervous systems. In some people, mainly those with focal 
neuropathy, the onset of pain may be sudden and severe. 
 Burning sensation in plants 
 Pain in calf muscles 
 Numbness of soles 
 Glove and stocking type of anesthesia 
 Weakness of lower limbs. 
 wasting of the muscles of the feet or hands 
 indigestion, nausea, or vomiting 
 diarrhea or constipation 
 dizziness or faintness due to a drop in blood pressure after standing or sitting 
up 
STAGES 
   
S.NO STAGES SYMPTOMS 
 
 
 
 
   1. 
 
 
 
ACUTE PAINFUL 
 
 
Burning, shooting stabbing 
pain, pins and needles, 
increased at nights 
absent/reduced reflexes                                                                        
 
   
   2. 
CHRONIC PAINFUL 
 
Severe symptoms as above 
(Hyperasthesia common) in 
poorly controlled DM 
 
 
    3. 
PAINLESS WITH 
COMPLETE/PARTIAL 
SENSORY LOSS  
 
Numbness/ deadness of feet 
painless injury, absent of jerks.                               
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Polymotor-Sensory Neuropathy  
 
                                         In the early phase of diabetic neuropathy, physical exami-
nation may be uninformative. Assessing the adequacy of perfusion is critical and 
easily accomplished by inspecting the toenails for capillary perfusion and palpating 
the tibialis posterior and dorsalis pedis arteries. As noted, a dry, cool foot with 
thickened or thin subcutaneous tissue and nonelastic skin is demonstrating 
microangiopathy, despite a palpable dorsalis pedis, indicating a likely positive result 
in decreased deep tendon reflexes at the ankle, vibratory sensation, position sense, 
hot-cold discrimination, or fine touch with monofilament test. Inability to perceive the 
monofilament indicates advanced neuropathy that would endanger the foot if injured. 
Peripheral neuropathic symptoms may also result from hyperglycemia-mediated nerve 
injury with no clinical evidence of loss of capillary density. Over time, paresthesias 
and burning pains usually improve, unless functional factors (endogenous or related to 
narcotic therapy) prolong or confound the symptomatology.  
Loss of the ankle reflex with sensory abnormalities indicates that the classic diabetic 
polyneuropathy is fully defined, with probable coexisting microangiopathy in the foot. 
Preventive foot care needs to be practiced to prevent skin breakdown. Patients should 
never walk barefooted because sharp objects penetrating the diabetic foot are often not 
perceived, leading to foot-threatening infections.  
Mononeuropathies  
                                      An individual nerve may be affected, such as the peroneal, 
resulting in footdrop, the seventh cranial nerve causing Bell’s palsy, or the extraocular 
nerves causing strabismus and diplopias. Similar to other causes of Bell’s palsy, the 
pathogenesis of these large-nerve injuries is thought to result from vascular injury; the 
paralysis is usually self-limiting and spontaneously improves over several months. In 
general, all these neuropathies have become less common as average HbA1c levels 
have fallen from above the 9% range over the last 10 years.  
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Occasionally, a diabetic mononeuritis with a localized region of pain can be 
misdiagnosed clinically as a mechanically mediated neuritis, such as a herniated 
intravertebral disk. If the appropriate imaging studies fail to demonstrate a mechanical 
etiology, a presumptive diagnosis of diabetes neuritis should be made and treatment 
aimed at glycemic control with physical therapy. On the other hand, diabetic neuritis 
of this type with constant pain may be initiated by mechanical factors. For example, a 
diabetic patient may acutely injure spinal nerves with a lifting maneuver, but this 
“neuromuscular pain” may become a continuing neuropathic pain as diabetic nerve 
fibers fail to heal in the presence of marked hyperglycemia. With no other etiologies 
evident, these patients eventually improve with more effective diabetic management.  
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DISTRIBUTION OF PAIN 
PATHOLOGY 
The factors leading to the development of diabetic neuropathy are not understood 
completely, and multiple hypotheses have been advanced.]It is generally accepted to 
be a multifactorial process. Development of symptoms depends on many factors, such 
as total hyperglycemic exposure and other risk factors such as elevated lipids, blood 
pressure, smoking, increased height, and high exposure to other potentially neurotoxic 
agents such as ethanol. Genetic factors may also play a role. Important contributing 
biochemical mechanisms in the development of the more common symmetrical forms 
of diabetic polyneuropathy likely include the polyol pathway, advanced glycation end 
products, and oxidative stress. 
Polyol pathway 
Hyperglycemia causes increased levels of intracellular glucose in nerves, leading to 
saturation of the normal glycolytic pathway. Extra glucose is shunted into the polyol 
pathway and converted to sorbitol and fructose by the enzymes aldose reductase and 
sorbitol dehydrogenase. Accumulation of sorbitol and fructose lead to reduced nerve 
myoinositol, decreased membrane Na+/K+ -ATPase activity, impaired axonal 
transport, and structural breakdown of nerves, causing abnormal action potential 
propagation. This is the rationale for the use of aldose reductase inhibitors to improve 
nerve conduction. 
Advanced glycation end products 
The nonenzymatic reaction of excess glucose with proteins, nucleotides, and lipids 
results in advanced glycation end products (ACE) that may have a role in disrupting 
neuronal integrity and repair mechanisms through interference with nerve cell 
metabolism and axonal transport. 
Oxidative stress 
The increased production of free radicals in diabetes may be detrimental via several 
mechanisms that are not fully understood. These include direct damage to blood 
vessels leading to nerve ischemia and facilitation of AGE reactions. Despite the 
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incomplete understanding of these processes, use of the antioxidant alpha-lipoic acid 
may hold promise for improving neuropathic symptoms. 
Related contributing factors 
Problems that are a consequence of or co-contributors to these disturbed biochemical 
processes include altered gene expression with altered cellular phenotypes, changes in 
cell physiology relating to endoskeletal structure or cellular transport, reduction in 
neurotrophins, and nerve ischemia. Clinical trials of the best-studied neurotrophin, 
human recombinant nerve growth factor, were disappointing. With future refinements, 
however, pharmacologic intervention targeting one or more of these mechanisms may 
prove successful. 
 
 
 
 
High 
glucose 
level
METABOLISM 
IN  NERVES 
AFFECTED
ACCUMULATION 
OF SARBITOL
DEFICIENCY OF 
MYOINOSITOL
INTERACTS 
PROTEIN 
METABOLISM
ALTERS THE 
PROTEIN 
STRUTURE
AFFECTS  
VASCULAR 
FUNCTION
DECREASED 
NITRIC ACID 
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NERVES
NERVE 
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INVESTIGATION 
 
NERVE CONDUCTION STUDY &ELECTROMYOGRAPHY: 
                               Nerve conduction velocity (NCV) test--also called a nerve 
conduction study (NCS)--is a measurement of the speed of conduction of an electrical 
impulse through a nerve. NCV can determine nerve damage and destruction.During 
the test, the nerve is stimulated, usually with surface electrode patches attached to the 
skin. Two electrodes are placed on the skin over the nerve. One electrode stimulates 
the nerve with a very mild electrical impulse and the other electrode records it. The 
resulting electrical activity is recorded by another electrode. This is repeated for each 
nerve being tested.The nerve conduction velocity (speed) is then calculated by 
measuring the distance between electrodes and the time it takes for electrical impulses 
to travel between electrodes. 
                                A related procedure that may be performed is electromyography 
(EMG). An EMG measures the electrical activity in muscles and is often performed at 
the same time as NCV. Both procedures help to detect the presence, location, and 
extent of diseases that damage the nerves and muscles. 
ELECTRO PHYSIOLOGICAL STUDIES: 
        In generalized symmetrical neuropathies there is impairment of motor and 
sensory conduction 
BIOTHESIMETRY: 
        Testing vibration sensation with a biothesiometer - application guidelines: 
                                    The biothesiometer has readings from 0 to 50 volts. It can be 
made to vibrate at increasing intensity by turning a dial.A probe is applied to part of 
the foot, usually on the big toe.The person being tested indicates as soon as he/she can 
feel the vibration and the reading on the dial at that point is recorded. The reading is 
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low in young normal individuals (i.e. they are very sensitive to vibration). In older 
individuals, the biothesiometer reading becomes progressively higher. From 
experience, it is known that the risk of developing a neuropathic ulcer is much higher 
if a person has a biothesiometer reading greater than 30-40 volts. 
 
MONOFILAMENT TEST: 
                 The 'Touch-Test' Sensory Evaluation (Semmens-Weinstein Monofilaments) 
application guidelines: 
• Occlude the patient's vision by using a shield or by having the patient look 
away or close his or her eyes. 
• Instruct the patient to respond when a stimulus is felt by saying 'touch' or 'yes'. 
• Prepare to administer the stimulus to the foot (dorsal or plantar surface). 
• Press the filament of the Touch 
• Test at a 90 degree angle against the skin until it bows. Hold in place for 
approximately 1.5 seconds and then remove. 
  To assure the validity of the sensory test findings: 
• The patient must not be able to view the administration of the stimuli so that 
false indications are avoided. 
• The nylon filament must be applied at a 90 degree angle against the skin until it 
bows for approximately 1.5 second before removing. 
• If the patient does not feel the filament, then protective pain sensation has been 
lost. 
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 ¸Õí¸¡Ä¢   -ACACIA CATECHU 
       §ÅÚ ¦ÀÂ÷: ¯Îì¨¸ ÁÃõ 
 
                                  þó¾¢Â¡Å¢Öõ À÷ÁÅ¢Öõ ÀÂ¢Ã¡Ìõ 
KINGDOM  : PLANTALE 
ORDER      : FABALES. 
 FAMILY     : FABACEAE. 
      GENUS      : ACACIA. 
      SPECIES    :CATECHU  
Synonyms: 
Acacia catechu 
Acacia catechuoides 
Acacia sundra 
Acacia walichiana 
Mimosa catechu 
 
Names in various languages: 
 
 English: black catechu 
 Malay: kachu 
 Latin:catechu 
 Telugu:Chandra 
 Malayalam: karingali 
 Sanskrit: khandira 
 Hindi: katha 
 Duk: kher 
ÀÂýÀÎõ ¯ÚôÒ: 
               Àð¨¼ 
               À¢º¢ý 
                §Å÷ 
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Í¨Å: 
           ÐÅ÷ôÒ(astrigent) 
 
¾ý¨Á: 
            º£¾õ 
 
À¢¡¢×: 
            ¸¡÷ôÒ 
 
¦ºö¨¸: 
       ÐÅ÷ôÀ¢ 
                        -  Ì½À¡¼õ ãÄ¢¨¸ ÅÌôÒ  
                                                   Àì¸ ±ñ-232 
ÅÇ¡¢ÂøÒ: 
 
             20-30 «Ê ¯ÂÃõ 
             ¸¢¨Ç¸û ÓûÙûÇ¨Å 
             þ¨Ä¸û Í¨½Â¡Ôõ 
             À¡ø ´¾¨Ä ÁÃò¾¢ý À¡ø §À¡ø þÕìÌõ 
             «§É¸ º¢È¢Â Áïºû ¿¢È âì¸û ¯¨¼ÂÐ. 
             À¢º¢ý ¯ûÇ ÁÃõ.  
- T.V.º¡õÀº¢Åõ À¢û¨Ç «¸Ã¡¾ 
- VOL-2   PAGE-142 
§ÅÕÈ¢Â ¿£÷  
“Ìð¼í¸Â§Ã¡¸íÌýÁõ ¦ÀÚÅÂ¢Ú 
¦¿ð¨¼ô ÒØ¾¢Á¢Õ ¿£¡¢Æ¢×-Å¢ð§¼ 
ÂÕí¸¡É ¸ò§¾Ì ÁïÍ¸§Á!¿øÄ 
¸Õí¸¡Ä¢ ¿£Ã¾¨É ¸ñÎ  “ 
                                       -Ì½À¡¼õ ãÄ¢¨¸ ÅÌôÒ Àì¸ ±ñ-232 
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þ¾É¡ø ¾£Õõ §¿¡ö¸û 
 
 ¦ÀÕ§¿¡ö-leprosy 
 «Æø ÌýÁõ-acid peptic disease 
 ¦ÀÕÅÂ¢Ú- ascitis 
 ÅÂ¢üÚô ÒØ §¿¡ö- helmenthic diseases 
 ÌÕ¾¢ì Ì¨ÈÅ¡ø Åó¾ ¾¢Á¢÷-neuritis due to anaemia 
 ¾¢Á¢÷Å¡¾õ- neuritis due to any cause 
 ¿£¡¢Æ¢× -diabetes mellitus   
   
CHEMICAL COMPOSITIONS: 
 Catechin 
 Epicatechin                 - anti oxidents 
 Catechunic acid            immune madulators 
 Atzelchin                      anti- viral 
 Catechinic tetramer      anti inflammatory action 
 Dicatechin 
 Gallochin 
 Gossypetin- anti inflammatory action 
 Epiafzelechin 
ACTIONS: 
 ANTI DIABETIC. 
 ASTRINGENT 
 ANTI DYSENTERIC. 
 ANTHELMENTIC. 
 CURES HAVIENESS. 
 ANTI CHOLESTEROL. 
86 
 
 ANTI ULCER 
 ANTI INFLAMMATORY 
 APHRODISIAC   
 IMMUNO MODULATOR 
IMPORTANT CHEMICAL COMPOUND: 
  “EPICATECHIN”- ACTION 
 PROMOTE REGENARATION OF BETA CELLS OF LANGERHANS. 
 CAPILLARY STABILIZING AGENT. 
 VASO PROTECTIVE AGENT. 
 IMPROVES BLOOD FLOW IN VESSELS. 
 NATURAL SOURCE OF VITAMIN B12 
“FLAVONOIDES”- PAIN KILLERS 
 INHIBITS THE COX-2 
 AN ANTI-OXIDENT  
 
  
  
 
 
KARUNGALI VER 
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METERIALS & METHOD 
PROTOCOL 
 
STUDY DESIGN: 
 The open clinical trial on VATHA KARSANAM was conducted at the OPD 
section of post graduates department of  Pothu Maruthuvam , Government Siddha 
Medical College, Arignar Anna Hospital, Chennai – 600 106 during the period  of 
2011-2013 
 
SAMPLE SIZE: 
 During this dissertation work on VATHA KARSANAM (Diabetic neuropathy) 
totally 40 patient of both sexes in the age group of above 40 are taken .  
 
 SELECTION CRITERIA: 
 Only diabetic patients more than 5 year 
 Both sexes 
 Obesity 
 Age above 40 
 Willing to give specimen of blood for investigation when required. 
 Willing to admitted in the hospital for one month or willing to attend the OPD 
once in 7 days 
 
EXCLUSION CRITERIA: 
 Idiopathic 
 Hereditary 
 Amyloidosis 
 Anaemia 
 Lyme disease 
 HIV 
 Metal poisioning 
 Gullian – Barrie syndrome 
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  Fabry’s disease 
 Tangier’s disease 
 Pregnant & lactating mothers 
 
WITHDRAWAL CRITERIA: 
Didn’t take the medicines regularly 
Didn’t turn for follow up once in a week 
Development of any infectious disease or side effects during their trial period 
 
EVALUATION OF CLINICAL PARAMETERS: 
 Patients are clinically evaluated by following parameters. 
 
Siddha system of  clinical diagnosis 
Poriyal Therthal – Mei, Vai, Kann, Mooku, Sevi 
Pulanal Therthal – Unarthal, Suvaithal, Parthal, Mugarthal, Kettal. 
Venaathal 
Mukkutra Nilaigal – Vali, Azhal, Iyam 
Ezhu Udal Kattugal – Saaram, Senneer, Oon Kozhuppu, Enbu, Moolai, Sukkilam. 
Envagai Thervu – Naa, Niram, Mozhi, Vizhi, Nadi, Sparisam, Malam, Moothiram. 
Case Sheet Proforma: 
 Patients will be treated with clinical signs and symptoms of Madhu megam. 
Complaints and Duration 
History of Past illness 
Personal History 
Personal Habits 
Family History 
 Systemic Examination 
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 Laboratory Investigation 
 Prognosis of the disease and management. 
 
 
INVESTIGATION: 
 The next step in Research oriented programme is investigation, to confirm the 
diagnosis predicted.  The investigations are carried out promptly and regularly before 
and after treatment. 
 All patients are subjected to routine clinical investigation which include 
 Urine sugar-fasting and post – prandial 
 Albumin and deposits in urine  
 Total count, differential count, Erythrocyte sedimentation rate, Haemoglobin 
and urea, cholesterol in blood. 
 Blood Sugar, fasting and post prandial ,other investigations like glucose 
tolerance test, glycosylated Haemoglobin (HbA1c) 
 Lipid profile 
 Biothesimetry 
 Monofilament test with 10microgram filament 
 Nerve conduction study (for affordable patients only).  
TRIAL DRUG: 
KARUNGALI VER KUDINEER  
INGREDIENTS: 
  KARUNGALI VER- ROOT OF ACACIA CATECHU 
DOSAGE: 
30 ml BD ( 20 mins before food) 
TRIAL PERIOD:  
 40 days 
 
 
  
  
 
 
KARUNGALI VER KUDINEER CHOORANAM 
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RESULTS AND OBSERVATIONS 
 
 The factors considered for the purpose of the study comprised of the following: 
 
 Age Distribution 
 Gender distribution  
 Thinai 
 Paruvakaalam 
 Occupational status 
 Socio economic Status 
 Food habits 
 Personal habits 
 Symptoms 
 Classifications of results according to Vali, Azhal & Iyyam 
 Udal kattugal 
 Enn vagai thervu 
 Naadi 
 Classification on the basis of Neikuri 
 Clinical progress 
 Urine sugar(F) 
 Urine sugar(pp) 
 Blood sugar(F) 
 Blood sugar(pp) 
 HbA1C 
 Monofilament test 
 Results after treatment.  
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AGE DISTRIBUTION 
SL.NO AGE NO. OF PATIENTS /20 PERCENTAGE 
1. 41-50 14 35% 
2. 51-60 10 25% 
3. 61-70 12 30% 
4. 71-80 4 10% 
 
 
 
Inference: 
According to the above mentioned data 30% of patients were in age 
groups 61-70 years, 10% of patients were in age group 71-80 year, 25% of 
patients were in age group 51-60 years and 35% of patients were in age group 
41-50 years. 
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GENDER WISE DISTRIBUTION: 
  
GENDER NO.OF PATIENTS PERCENTAGE 
MALE             24            60% 
FEMALE             16            40% 
 
 
 
 
 
 
 
INTERFERENS: 
   60% affected were men 
  40% affected were women 
 
 
 
 
 
  
, MALE, 60%
female 40%
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THINAI: 
 
SL.NO THINAI NO. OF PATIENTS /20 PERCENTAGE 
1. Kurinji 0 0% 
2. Mullai 0 0% 
3. Marutham 4            10% 
4. Neithal 36 90% 
5. Paalai 0 0% 
 
 
 
 
 
 
Inference: 
From the above data 90% of patient from  Neithal and10% of cases from marutham. 
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THINAI
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PARUVAKAALAM: 
SL.NO. PARUVAKAALAM NO. OF PATIENTS /20 PERCENTAGE 
1. 
Kaar kaalam  
(Aavani & purattasi) 
Aug 16 to Oct15 
7 17.5% 
2. 
Koothir kaalam 
(Iypasi &karthigai) 
Oct 16 to  Dec15 
5 12.5% 
3. 
Munpani kaalam 
(Margazhi & Thai) 
Dec16 to Feb15 
3 7.5% 
4. 
Pinpani kaalam 
(Masi& Panguni) 
Feb16 to June15 
4 10% 
5. 
Elavenir kaalam 
(chithirai & vaikaasi) 
April16 to June15 
8 20% 
6. 
Mudhuvenir kaalam 
Aani & Aadi 
June16 to Aug 15 
13 32.5% 
 
 
 
Inference: 
17.5% of case came in Kaar kaalam and 12.5% of case in kuthir kaalam,7.5% of cases 
in munpani kaalam,10% of cases in Pinpani kaalam, 20% of cases in  ilavenil kaalam, 
32.5% of cases in muthuvenil kaalam.  
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OCCUPATIONAL STATUS 
 
 
 
 
 
 
 
 
 
  
`  
 
Inference: 
52.5% of cases were Professionals. 
15% of cases were Retired persons are coming under others. 
32.5% of cases were house wives 
 
 
  
52.5
15
32.5
Sales
proffesionals
others
housewives
SL.NO OCCUPATION NO OF PATIENTS /20 PERCENTAGE 
1. Professionals 21        52.5% 
2. Others 6 15% 
3.  House wives 13 32.5% 
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SOCIO ECONOMIC STATUS 
 
Sl.No. Socio Economic Status No. of Patients /40 Percentage 
1. Low income group (below 10000/month) 8 20% 
2. Middle income group (10000-20000/ month) 28 70% 
3. High income group (above 20000/month) 4 10% 
 
  
 
 
Inference: 
70% of cases belong to middle income group and 20% of patients belong to 
lower income group. 10% of cases belong to high income group.  
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FOOD HABITS 
 
SL.NO. FOOD HABIT NO. OF PATIENT / 20 PERCENTAGE 
1. Vegetarian 16 40% 
2. Mixed diet(including non-veg) 24 60% 
 
 
 
 
Inference: 
60% of cases were mixed diet. With non veg diet  
40% of cases were Vegetarian.  
Vegitarian
40%
Mixed diet
60%
Food Habit
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PERSONAL HABITS 
 
SL.NO. PERSONAL HABIT NO. OF PATIENTS / 40 PERCENTAGE 
1. Smoker 10 25% 
2. Alcoholic 4 10% 
3. Tobacco chewing 2 5% 
4. Others 24 60% 
 
 
 
  
Inference: 
60% of patients had no bad habits, 25% of cases were smoker and .10% of cases were 
alcoholic, 5% of cases were Tobacco Chewing. 
  
Smokers
Alcoholic
Tobacco 
Chewing None
25%
10%
5%
60%
Personal Habit
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SYMPTOMS 
SL.NO SYMPTOMS NO. OF PATIENTS/ 40 PERCENTAGE 
1. Burning sensation in palms 36 90% 
2. Pain in calf muscles 12 30% 
3. Numbness of soles 32 80% 
4. Glove and stocking type of anaesthesia 15 38% 
5. Weakness of lower limbs 32 80% 
 
 
Inference: 
            90% of cases had burning sensation in palms 80% of cases had numbness over 
the soles& palms,75% 0f cases had weakness of lower limbs, 38% of cases had glove 
& stocking type of anesthesia 30% of cases had pain in calf muscles. 
 
 
 
 
                                               
burning sensation in palms
weakness of lower limbs
numbness of soles
glove &stocking anaesthesia
pain in calf muscle
90%
80%
80%
38%
30%
Symptoms
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  VATHAM 
SL.NO. VATHAM NO. OF PATIENTS / 40 PERCENTAGE 
1. Pranan 0 0% 
2. Abanan 16 40% 
3. Viyanan 40 100% 
4. Uthanan 0  0% 
5. Samanan 16 40% 
6. Nagan 0 0% 
7. Koorman 9 22.5% 
8. Kirugaran 0 0% 
9. Devathathan 17 85% 
10. Thananjeyan 0 0% 
 
 
Inference: 
Viyanan was affected in 100% of patients and Devathathan was affected in 85% of 
patient. Abanan and samanan were affected in 40% of cases. koorman affected in 
22.5%  of cases.  
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
0%
40%
100%
0%
40%
0% 0%
85%
0%
22.50%
pe
rc
en
ta
ge
vatham
Vatham
103 
 
PITHAM 
SL.NO. PITHAM NO.OF PATIENT /20  PERCENTAGE 
1. Anar pitham 16 40% 
2. Ranjagam 10 25% 
3. Saathagam 40 100% 
4. Prasagam 0 0% 
5. Alosagam 9 22.5% 
 
 
 
 
Inference: 
Anarpitham was affected in 40% of patients , sathagam was affectedin 100% of 
patients ,alosagam was affected in 22.5%  of cases. Ranjagam was affected in 25% of 
cases. 
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KAPAM 
 
 
 
 
Inference: 
Kilethagam was affected in 40% of patients and Santhigam in 25% of patients. 
tharpagam was affected in 22.5% of case 
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SL.NO. KAPAM NO. OF PATEINTS /40 PERCENTAGE 
1. Avalambagam 0 0% 
2. Kilethagam 16 40% 
3. Pothagam 0 0% 
4. Tharpagam 9 22.5% 
5. Santhigam 10 25% 
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UDAL KATTUGAL 
 
 
SL.NO. UDAL KATTUGAL NO. OF PATIENT / 20 PERCENTAGE 
1. Saaram 40 100% 
2. Seneer 40           100% 
3. Oon 20 50% 
4. Kozhuppu 0 0% 
5. Enbu 10 25% 
6. Moolai 0 0% 
7. Sukkilam 0 0% 
 
 
 
 
 
Inference: 
Saram affected 100% 
Seneer affected 100%   
Enbu  aaffected 25%  Oon affected 50% 
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ENVAGAI THERVUGAL 
 
 
SL.NO. ENVAGAI THERVUGAL NO. OF PATIENT / 20 PERCENTAGE 
1. Naa 26 65% 
2. Niram 10 25% 
3. Mozhi 0 0% 
4. Vizhi 9 22.5% 
5. Naadi  40 100% 
6. Sparisam 40 100% 
7. Malam 5 12.5% 
8. Moothiram 16           40%      
 
 
 
 
Inference: 
       Naadi was affected in 100% of patients and 100% of patients sparisam was 
affected 
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NAADI 
 
SL.NO. NAADI NO. OF PATIENT / 20 PERCENTAGE 
1. Kappa Pitham 0 0% 
2. Vaatha Pitham 35 87.5% 
3. Pitha Vaatham 0 0% 
4. Vaatha Kapam 0 0% 
5. Kapa Vaatham 5         12.5% 
 
 
 
 
 
Inference: 
87.5% of patient’s vatha pitham naadi was felt and 12.5% of cases kabha vatha 
naadi was felt.  
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NEIKURI 
 
SL.NO. NEIKURI NO. OF PATIENT / 20 PERCENTAGE 
1. Vatham  (Spreads like Snake) 31 77.5% 
2. Pitham (Spreads like Ring) 2 5% 
3. Kapam  (Stands like Pearl) 7 17.5% 
 
 
 
 
Inference: 
77.5% of cases show Vatha neikuri, 17.5% shows Kapha neikuri and 05% 
shows Azhal neikuri. 
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CLINICAL PROGRESS 
SL.NO SYMPTOMS 
NO. OF PATIENTS/ 40 PERCENTAGE 
Before 
Treatment 
After 
Treatment 
Before 
Treatment 
After 
Treatment 
1. Burning sensation in palms 36 6 90% 14% 
2. Pain in calf muscles 12 3 30% 7.5% 
3. Numbness of soles 32 8 80% 20% 
4. Glove and stocking type of anaesthesia 15 2 37.5% 5% 
5. Weakness of lower limbs 32 4 80% 10% 
 
 
 
Inference 
 
             burning sensation in palms has reduced from 90% to 14%,  numbness over the 
soles& palms had reduced from 80% to 20%, weakness of lower limb had reduced 
from 80% to 10%, glove & stocking type of anesthesia has reduced from 37.5% to 
5%, pain in calf muscles has reduced from 30% to 8%. 
   
90%
30%
80%
38%
80%
14% 8%
20%
5% 10%
Clinical progress
Column2 Before Treatment After Treatment
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URINE SUGAR LEVELS (FASTING) 
  
URINE SUGAR 
(FASTING) 
Before 
treatment 
percentage After treatment percentage 
           ++         24     60%             0             0% 
            +         16     40%             8             20% 
            nil          0                   32             80% 
 
 
 
 
 
Inference: 
 
                  Urine (F) becomes nil in 80% 0f cases. 
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Urine sugar( pp) 
Urine sugar 
(pp) 
Before 
treatment 
percentage After 
treatment 
Percentage 
 
 
+++ 
       
        24 
 
           60% 
         
 
            0 
 
      0% 
 
++ 
  
        16 
 
            40% 
 
           2 
 
       5% 
 
+ 
 
         0 
 
             0% 
 
           6 
 
       15% 
 
nil 
 
         0 
                                                          
              0%             32        80% 
 
 
 
Inference: 
     In 80% of cases the urine sugar (pp) becomes nil. 
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Blood sugar (fasting) 
Blood 
sugar(fasting)mg/dl 
Before 
treatment 
percentage After 
treatment 
percentage 
60-109       2 5% 32 80% 
110-129       4 10% 6 15% 
130-149       6 15% 2 5% 
Above 150       28 70% 0 0% 
 
 
 
Inference: 
After treatment the fasting blood sugar level fall within 60-70mgs/dl in 80% of cases 
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Blood sugar (post prondial) 
Blood sugar 
(pp) mgs/dl 
Before 
treatment 
percentage After 
treatment 
percentage 
100-149 0 0% 32 80% 
150-199 4 10%             4 10% 
200-249 12 30% 4 10% 
Above 250 24 60% 0 0% 
 
 
 
 
Inference   : 
     The pp blood sugar levels falls between 100-149mgs/dl in 80% of cases 
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HbA1C REPORT 
HbA1C Before 
treatment 
percentage After 
treatment 
percentage 
Good control 
5.7-7% 
 
       0 
 
         0% 
 
       25 
 
62.5% 
Fair control 
7-8% 
 
       12 
 
        30% 
 
       10 
 
      25% 
Poor control 
Above 8% 
   
       28 
 
       70% 
 
         5 
   
      12.5% 
 
 
Inference: 
   HbA1C reports shows the improvement of good control from 0% to 62.5% 
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MONOFILAMENT TEST: 
 
Monofilament 
test with 10mg 
filament 
Before 
treatment 
percentage After 
treatment  
percentage 
 
Impaired 
     
       40 
 
       100% 
 
        8 
 
         20% 
 
Normal  
 
        0 
 
        0% 
 
       32 
 
         80.% 
 
 
Inference: 
       80% of cases get normal in monofilament test after treatment. 
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PROGNOSIS 
 
SL.NO. Results NO. OF PATIENT / 40 PERCENTAGE 
 1. Good improvement 32 80% 
2. Moderate Improvement               6 15% 
3. Poor Improvement 2 5% 
 
 
         
 
 
Inference: 
 Based on blood sugar level and mono filament test  80% of Patients show 
good improvement, 15% of shows moderate improvement and 5% of cases shows 
poor improvement 
 
 
80%
15%
5%
Results
Good improvement
Moderate Improvement
Poor Improvement
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DISCUSSION 
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DISCUSSION 
The sweeping change in the life style and the food habits of people in the modern 
world has absolutely played a significant role in the health aspect of 
humanity.VATHA KARSANAM is the disorders of peripheral nerves either sensory 
motor or mixed symmetrical and affecting distal parts of the limbs more than 
proximal.About26% of world diabetic populations having neuropathy. In this study, 
the various factors were taken into consideration with the small group of forty 
patients. The aspects that were looked into for study are discussed as follows: 
AGE WISE ANALYSIS: 
  The study shows that the vathakarsanam (dm neuropathy)is common among the age 
group of 40-80. In 41-50years- 35% cases, 51-60 years- 25%, 61-70years -30% of 
cases & 71-80years- 10%. Being the complication of diabetes it occurs in above all 
the age depending upon the control of blood sugar. 
GENDER WISE ANALYSIS: 
           It shows that men are mostly in poor control of diabetes than female. i.e. male-
60%, female-40%. But usually occurs in both sexes. 
THINAI(LAND): 
                         According to this study 90% of cases reported in patients who live in 
Neithal. Remaining 10% cases reported from marutham . Moreover neithal land 
makes people obese which cause the disease (Siddha Maruthuvanga Churukkam – P -
256). 
 
 PARUVA KAALAM (SEASONAL INCIDENCE): 
                          The seasonal changes does not have any impact on this study. But 
most of the cases reported in muthuvenil kallam-32.5%, kaarkalam-
17.5%,munpanikaalam-7.5%,kuthir kaalam-12.5%, pinpanikaalam-10%, elavenil 
kaalam-20%. 
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OCCUPATIONAL ANALYSIS: 
                         Due to sedentary life and irregular food habits working people (52.5%) 
having high rate of incidents. Next housewives (32.5%) having higher incidents due to 
lack of physical work. Retired people having 15% of incidences..  
 
 
 
SOCIO ECONOMIC STATUS:   
  People belonging to all groups are affected in vathakarsanam. Middle income groups 
were reported 70% in this study. Low income group was affected 20%,high income 
group cases affected 10%.     
DIETARY HABITS:     
       Vatha karsanam is more among all groups particularly in mixed diet ( including 
non-vegetarian diet) people. Fast food & junk food habits aggravated the symptoms of 
the disease due to increase of blood sugar level,  
“c‰gé¡F« ghš beŒ ahš  Ïiw¢Á fŸshš” 
- ô» it¤Âa Áªjhkâ g¡f« - 146 
As per  Agasthiar, 
  “bfhG¤j Ûåiw¢Á nghij 
   XJ ÚçêÎ nru” 
           - Á¤j kU¤Jt« - g¡f« 470 
 
 
MUKUTTRAM CLASSIFICATION: 
 
VALI: viyanan , devathathan, , abanan are affected.  
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                 The action of abanan is to regulate the function of excretion of urine and 
feaces.  The derangement  of the function of abana leads to polyuria and constipation. 
It was deranged in 40% cases.   
                 Viyanan exists all over the body, it lives in skin and activate the 72000 
Nadi’s.  It helps the movement of all organs and sensation.  In vathakarsanam viyanan 
is affected and so it leads to pain all over the body, pain and pricking sensation 
numbness of palms & soles. It was deranged in 100% of cases. 
                Devathathan  is responsible for general ability of  body and mind it was 
affected in 85% of cases. Derangements of this vatham  leads to weakness of lower 
limbs and tiredness.  
                 Koorman  was affected in 22.5% of cases. It is responsible for vision. 
AZHAL: 
                Anar pitham is affected in 40% of cases.  In general Anar pitham action is 
exactly between the stomach and small intestine which means the pancreatic action is 
mainly maintained by Anarapitham.  Its derangement causes DIABETES. 
                   Sathaga pittham is affected in 100% of patients. 
                   Alosaga pittham  is responsible for vision . It is affected in 22.5% due to 
cataract. 
                  Ranjaga pitham is responsible for changes in blood. It was affected  in 25% 
cases. 
 
KABHAM: 
                 Kilethagam  was affected in 40% cases. The function of Kilethagam is to 
make the contents (food) of the stomach ready for digestive process.  If the function 
get deranged the initial phase of metabolism gets affected. 
                Santhigam affected in 25% of cases. Tharpagam was affected in 22.5% due 
to vision distrubences. 
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EZHU UDAL KATTUGAL: 
             Vatha karsanam saram, seneer, oon,enbu are affected. 
              Saram, seneer were affected in 100% of patients. Oon was affected in 50% of 
cases.  Enbu was affected in 25% of cases. 
ENVAGAI THERVUGAL: 
           NAADI & SPARISAM were affected in 100% of patient. Naa affected in 65% 
of cases, moothiram affected in 40% of cases.vizhi affected in 22.5% 0f cases. Niram 
affected in 25%. 
NEIKURI: 
            78% of patient vatha neikuri.17.% kabha neikuri.5% of pitha neikuri. 
NAADI:  
         In all the patient vaatha  thontha naadi is prominent. 
        i.e  kapha vatham- 12.5% 
              vatha pitham-87.5% 
 SIGNS AND SYMPTOMS: 
              The main symptoms of vathakarsanam burning sensation, pain in calf 
muscles, numbness of soles, glove & stocking type of anaesthesia,  weakness of 
lower limbs. All the symptoms  has markedly improved clinically and their 
conditions was good. 
           Urine sugar fasting & post prandial has become normal in 80% of cases. 
            Blood sugar fasting & post prandial has improved 75% and 70% of the 
cases respectively. 
           Blood sugar in the range of above 250mgs/dl shows good response 
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           HbA1C shows good control in 62.5% of cases shows the precious 
management  and control of vathakarsanam. 
Mono filament test: 
   This shows high percentage of improvement in 80% 0f cases. 
  
TREATMENT: MUKKUTRA THEORY 
              The disease and treatment are based primarily on the derangement of UYIR 
THATHUKKAL which again  is based on theFIVE ELEMENTS theory.  Incidence of 
VATHA KARSANAM and treatment are also based on these primary principles of 
Siddha medicine. 
“THUVARPPU SUVAI”-MAAN + KATTRU 
In vatha karsanam  vali and thee pootham are commonly affected.THUVARRPU 
SUVAI mainly composed of kattru that is vali. So the drug act on OPPURAI basis. 
               The fusion of Thee +Thee gives raise to pitham.  If there is excess of these 
boothas in the body, it is excreted in the urine, dryness of mouth. The medicine chosen 
for the   treatment of vathakarsanam  has “THUVARPPU SUVVAI” which is having  
the property of settle down the vatham as well as the pitha kuttram.  There by the drug 
plays an important role on vathakarsanam. So the trial drug was act on ETHIRURAI 
basis .        
     According to above theory the drug acts in the basis of KALAPPURAI basis. 
              Based on the animal study done in vels university reveals that  KARUNGALI 
VER KUDINEER is safe for prolong use for a life time disease madhumegam 
(diabetes). 
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QUALITATIVE ANALYSIS: 
 The sodium corbonate extract of the medicines were tested for acid 
radicals, basic radicals and miscellaneous compounds. 
 The results shows karunkali ver kudineer presence of iron,chloride, zinc, 
and reducing sugar. 
TOXICOLOGICAL STUDY: 
 Acute and sub acute toxicity studies were conducted on  experimental rats at 
vels college of pharmacy. 
 The hematological  parameters, liver function test, renal function test and 
histopathology of vital organs shows no toxicity effect for KARUNGALI 
VER KUDINEER. 
   PHARMACOLOGICAL STUDY: 
    KARUNGALI VER KUDINEER shows significant analgesic effect in higher doses 
STATISTICAL ANALYSIS: 
 In both subjective and objective parameters were statistically significant. 
 The statistical analysis reveals that the drug has good potency to treat the 
disease vatha karsanam. 
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SUMMARY 
           The clinical study on VATHA KARSANAM was carried out in Post graduate 
department of Maruthuvam, Government Siddha Medical College, Arignar Anna 
Hospital,     Chennai –106 during the period of 2011-2013. 
 A total of 40 patients were treated in the O.P and I.P department. The clinical 
and pathological assessment was carried out on the basis of both Siddha and modern 
aspects.   
 All the 40 patients were treated with KARUNGALI VER KUDINEER (30 ml  
20 minutes before food). The duration of the treatment was fixed as 45 days.  The 
responses were assessed 7 days once for all the patients 
 The peak incidence of vatha karsanam was found in all the study group of 
both sex. It  depends upon the control of sugar level in blood. 
 The prevalence of the disease was high among middle class population 70%,  
22.5%, and High class population 7.5%. 
 Among dietary patterns, 60% patients consume Mixed diet with non vegetarian 
diet 
 Regarding personal habits, 25% were smoker, 10% were Alcoholic, 5% were 
betalnut & Tobacco chewer,  
 Out of 40 patients, 52.5%were working peoples 32.5% were house wife, 
15%were other workers.. 
 From selected 40 patients, 17.5% comes under Kaarkaalam, 12.5% comes 
under Kuthirkaalam, 17.5% comes under Munpani, 20% comes under Elavenil, 
32.5% comes under Mudhuvenil kaalam 
 In vatham – viyanan (100%),abanan and samanam  (40%), koorman (22.5%) 
devathathan(85%) were affected 
 In pitham - Sadhaga Pitham (100%), Ranjaga pitham (25%), Aanalagam 
(40%), Aalosagam (22.5%) were affected. 
 In Kapham - Kilethagam (40%), tharpagam (22.5%)and Santhigam (25%) were 
affected. 
 Among Ezhu Udal Kattugal, Saaram,& seneer (100%), oon (50%) and Enbu 
(25%) were affected. 
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 Among Envagai Thervugal, naadi & sparisam (100%) Vizhi (22.5%), Niram 
(25%), Naa (25%), Moothiram (40%), and Malam (12.5%)  were affected. 
 Naadi in vatha karsanam patients felt as, Vatha pitham naadi (87.5%) and 
kabha vatham (12.5%).. 
 In biochemical analysis the karunkali ver kudineer has iron and zinc 
presentation. So it shows the  effect of drug in vatha karsanam.(dm neuropathy) 
 The toxicity study shows the drug has no toxicity in higher doses too. So it is 
very safe for prolong use. 
 The preclinical studies shows the drug shows significant  response in both 
central & peripheral acting analgesic action 
 The symptoms fully recovered in 70% of patients 
 The HbA1C report shows good control in 62.5% of cases 
 The pre clinical data were analysed statistically and observed that the drug are 
significant in relieving the symptoms 
 The drug has easily available  
 More over the drug itself has a hypoglycaemic effect and analgesic. This 
combination of drug should be helpful to the patient to take single drug for the 
disease madhumegam (diabetes) and its major complication vatha karsanam 
(dm neuropathy) 
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CONCLUSION 
 The trial drug  used in this study are easily available  in south India 
 The preparation of the trial drug is quick and easy 
 The drug is like drinking water and hence the oral route of administration is easy. 
 It may be noted that the drug is a safe and effective one for vatha karsanam 
 The pharmacological study revealed that the KARUNGALI VER KUDINEER 
yielded BETTER results in rat models and there was no toxicity in the drug. 
 In clinical study also there was no hypoglycemic complications were observed. 
Hence it could be administrated even for longer period if required. 
 The pharmacological study revealed that the KARUNGALI VER KUDINEER 
yielded good results in rat models and there was no toxicity in the drug.. 
 The statistical analysis proved significance  of clinical improvement with the 
treatment. 
 Hence the KARUNGALI VER KUDINEER has proved  its efficacy of reduces the 
blood sugar level and the neuropathic pain also. So the authour hope that this 
medicine should be a very hopeful remady for a world wide disease (diadetes) 
mathumegam and its major complication, vatha karsanam( dm neuropathy)  
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ANNEXURE –I 
 
CHEMICAL ANALYSIS OF TRIAL MEDICINES 
Preparation of Sodium Carbonate extract: 2 gm of the sample is mixed  5 gm of 
Sodium carbonate and taken in a 100 ml beaker and 20 ml of distilled water is added.  
The solution is boiled for 10 minutes, cooled and then filtered.  The filtrate is called 
sodium carbonate extract. 
 
S.No. 
 
Experiment 
Inference 
Drug  Drug  
1 Test for Acid Radicals   
a. Test for Sulphate 
2 ml of the above prepared 
extract is taken in a test tube.  To 
this add 2ml of 4% Ammonium 
oxalate solution. 
Absence of              
White  Precipitate  
Absent 
b. 2ml of extract is added with 2ml 
of dilute hydrochloric acid until 
the effervescence ceases off.  
Then 2ml barium chloride 
solution is added. 
Absence of              
White  Precipitate 
Absent 
2. Test for Chloride: 
2ml of extract is added with 
dilute nitric acid till the 
effervescence ceases.  Then 2ml 
of silver nitrate solution is added. 
 
 white precipitate 
is developed. 
 
Present  
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3. Test for Phosphate 
2ml of the extract is treated with 2 ml of 
Ammonium molybdate  solution and 2ml of 
concentrated nitric acid. 
Yellow Precipitate 
is obtained. 
Absent  
4. Test for Carbonate: 
2ml of the extract is treated with 2ml of 
magnesium sulphate solution. 
Absence of white 
precipitate 
Absent 
5. Test for Sulphide: 
1 gm of the substance is treated with 2ml of 
concentrated Hydrochloric acid 
Absence of Rotten 
egg smelling  
Absent 
6. Test for Nitrate: 
1gm of the substance is heated with copper 
turnings and concentrated sulphuric acid and 
viewed the test tube vertically down. 
Absence of reddish 
brown gas. 
Absent 
7. 
a. 
Test for Fluoride and oxalate 
2ml of the extract is added with 2ml of dilute 
acetic acid and 2ml of calcium chloride 
solution and heated.  
Absence of white 
precipitate 
Absent 
b. 5 drops of clear solution is added with 2ml of 
dilute sulphuric acid and slightly warmed to 
this, 1 ml of dilute potassium permanganate 
solution is added.  
Absence of 
KMNO4 solution 
discolourisation.  
Absent 
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8. Test for Nitrite 
3 drops of the extract is placed on a filter paper.  
On that, 2 drops a Acetic Acid and 2 drops of 
Benzidine solution is placed. 
Absence of 
yellowish red 
colour  
Absent 
9. Test for Borate 
2 pinches of the substance is made into paste by 
using Sulphuric acid and Alcohol (95%) and 
introduced into the blue flame. 
Absence of Green 
tinged flame 
Absent  
II. TEST FOR BASIC RADICALS  
10. Test for lead 
2 ml of the extract is added with 2 ml of 
Potassium iodide solution 
Absence of Yellow 
precipitate 
Absent 
11a Test for Copper 
One pinch of substance is made into paste with 
concentrated Hydrochloric acid in a watch 
glass and introduced into the non luminous part 
of the flame. 
Bluish green 
coloured flame is 
obtained. 
Absent  
b. 2ml of the extract is added with excess of 
Ammonia solution 
Absence of deep 
blue 
Absent 
12. Test for Aluminium 
To the 2 ml of extract.  Sodium Hydroxide 
solution is added in drops to excess. 
 Absence of     
White precipitate. 
Absent  
13a Test for Iron 
To the 2 ml of extract, 2 ml of Ammonium 
Thiocyanate solution is added. 
Blood red colour is 
obtained. 
Present  
b. To the 2 ml of extract, 2 ml of Ammonium 
Thiocyanate solution and 2 ml of concentrated 
Nitric Acid is added. 
Blood red colour is 
obtained. 
present  
14. Test for Zinc 
To the 2 ml of extract Sodium Hydroxide 
solution is added in drops to excess. 
White precipitate is 
obtained 
Present  
 15. Test for Calcium 
2 ml of the extract is added with 2 ml of 4% 
Ammonium Oxalate solution. 
 Absence of      
White precipitate.  
Absent  
16. Test for Magnesium 
 2ml of extract, Sodium Hydroxide solution is 
added in drops to excess. 
 Absence of   
White precipitate. 
Absent 
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17. Test for Ammonium 
 2 ml of extract few ml of Nessler’s Reagent 
and excess of Sodium Hydroxide solution are 
added. 
 
Absence of   
Reddish brown 
precipitate  
Absent  
18. Test for Potassium 
A pinch of substance is treated with 2 ml of 
Sodium Nitrite solution and then treated with 2 
ml of Cobal Nitrate in 30% glacial Acetic acid. 
Absence of Yellow 
precipitate 
Absent 
19. Test for Sodium 
2 pinches of the substance is made into paste by 
using Hydrochloric acid and introduced into the 
blue flame. 
Absence of Yellow 
colour flame  
Absent  
20. Test for Mercury 
2 ml of the extract is treated with 2 ml of 
Sodium Hydroxide solution. 
Absence of yellow 
precipitate 
Absent  
21. Test for Arsenic 
2 ml of extract is treated with 2 ml of silver 
Nitrate solution 
  Absence of                                                                                                                    
Yellow precipitate. 
Absent
22. Test for Starch 
2ml of extract is treated with weak iodine 
solution 
Absence of                                                                                                                    
Blue colour  
Absent
23. Test of reducing Sugar 
5ml of Benedicts qualitative solution is taken in 
a test tube and allowed to boil for 2 minutes 
and added  10 drops of the extract and again 
boiled for 2 minutes.  The colour changes are 
noted. 
Green colour is 
obtained. 
Present 
24.  Test of  the alkaliods               2ml of the 
extract is treated with  2ml of potassium iodide 
solution 
Red colour 
developed 
Present   
 
                                  
25. Test for proteins: (biuret test) 
         Take 2 ml of solution and 2ml of 5% 
sodium hydroxide, mix and add 2 drops of 
copper sulphate solution. 
Absence of violet 
colour 
Absent 
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RESULTS:   
 
The given sample contains. 
Drug- karungali ver kudineer – 1gm  
Chemicals present: 
Chloride 
Iron 
Zinc 
Reducing sugar 
alkaloides 
. 
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ANNEXURE II 
ACUTE AND SUB ACUTE TOXICITY STUDY ON KARUNGALI VER 
KUDINEER 
Animals  
 Mice of either sex weighing 25-30g and rats weighing 210-240g were obtained 
from the animal house of Vels University. The animals were used with the approval of 
the Institute animal ethics committee and obtained from Vels University, Chennai. 
They were fed with a balanced standard pellet diet and maintained under standard 
laboratory conditions, providing 24-280C temperature, standard light cycle (12 h light, 
12 h dark) and water ad libitum.  
 Animals were kept in cages with raised floors of wide mesh to prevent 
coprophagy. Animal welfare guidelines were observed during the maintenance period 
and experimentation. The rats were randomly assigned to control and different 
treatment groups, six animals per group. The animals were acclimatized for one week 
under laboratory conditions.  
ACUTE TOXICITY STUDY-OECD 425 GUIDELINES 
 Acute oral toxicity test for the Karungali Ver Kudineer was carried out as per 
OECD Guidelines 425. As with other sequential test designs, care was taken to ensure 
that animals are available in the appropriate size and age range for the entire study. 
The test substance is administered in a single dose by gavage using a stomach tube or 
a suitable intubation cannula. The fasted body weight of each animal is determined 
and the dose is calculated according to the body weight. After the substance has been 
administered, food was withheld for a further 2 hours in mice.  
 The animals were observed continuously for the first 4 h and then each hour for 
the next 24 h and at 6 hourly intervals for the following 48 h after administering of the 
test drug, to observe any death or changes in general behaviour and other 
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physiological activities. Single animals are dosed in sequence usually at 48 h intervals. 
However, the time interval between dosing is determined by the onset, duration, and 
severity of toxic signs. Treatment of an animal at the next dose was delayed until one 
is confident of survival of the previously dosed animal. General behavior, respiratory 
pattern, cardiovascular signs, motor activities, reflexes, change in skin and fur, 
mortality and the body weight changes were monitored daily. The time of onset, 
intensity, and duration of these signs, if any, was recorded.  
SUB-ACUTE TOXICITY  
 In a 28-days sub acute toxicity study, twenty four either sex rats were divided 
into four groups of 6 rats each. Group I that served as normal control was 
administered with distilled water (p.o.) while groups II, III and IV were administered 
daily with the Karungali Ver Kudineer (p.o.) for 28 days at a dose of 2, 4 and 8ml/kg 
respectively. The animals were then observed daily for gross behavioural changes and 
any other signs of subacute toxicity.  
 The weight of each rat was recorded on day 0 and weekly throughout the 
course of the study, food and water consumption per rat was calculated. At the end of 
the 28 days they were fasted overnight, each animal was anaesthetized with 
diethylether, following which they were then dissected and blood samples were 
obtained by cardiac puncture into heparinised tubes. The blood sample collected from 
each rat was centrifuged with 3000 X g at 4oC for 10 min to separate the serum and 
used for the biochemical assays.  
 
Hematological and blood biochemical analyses  
 After 4 weeks of the once daily treatment of Karungali Ver Kudineer, all 
animals were kept fasted for 16-18 h and then anesthetized with anesthetic ether on 
the 28th day. Blood samples for hematological and blood chemical analyses were 
taken from retro orbital vein. Heparinized blood samples were taken for determining 
complete blood count (white blood cell count, differential white blood cell count, 
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platelet count, red blood cell count, hematocrit, and hemoglobin) by semiautomated 
hematology analyzer.  
 The serum from non-heparinized blood was carefully collected for blood 
chemistry and enzyme analysis (glucose, creatinine, total protein, albumin, total and 
direct bilirubins, serum glutamate-oxaloacetate transaminase (SGOT), serum 
glutamate pyruvate transaminase (SGPT), and alkaline phosphatase (ALP)) were 
automatically determined using autoanalyzer. 
Necropsy  
 All rats were sacrificed after the blood collection. The positions, shapes, sizes 
and colors of internal organs were evaluated. The Spleen, Testes, Pancrea, Lung, 
Liver, Brain, Heart, Stomach, Intestine, Bone, Ovary, and Kidney tissues were excised 
from all rats to visually detect gross lesions, and weighed to determine relative organs’ 
weights and preserved in 10% neutral formalin for histopathological assessment. The 
tissues were embedded in paraffin, and then sectioned, stained with haematoxylin and 
eosin and were examined microscopically. 
Statistical analysis 
 Values were represented as mean ± SEM. Data were analyzed using one-way 
analysis of variance (ANOVA) and group means were compared using the Tukey-
Kramer Multiple Comparison test using Graph Pad Instat-V3 software. P < 0.05 was 
considered significant. 
RESULTS 
 All the animals from control and all the treated dose groups up to 400 mg/kg 
survived throughout the dosing period of 28 days. No signs of significant intoxication 
were observed in animals from lower to higher dose groups during the dosing period 
of 28 days. Animals from all the treated dose groups exhibited comparable body 
weight gain with that of controls throughout the dosing period of 28 days.  
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 Food consumption of control and treated animals was found to be comparable 
throughout the dosing period of 28days. Ophthalmoscopic examination, conducted 
prior to and at the end of dosing period on animals from control and all the treated 
dose groups did not reveal any abnormality. The results of haematological 
investigations revealed following no significant changes in the values of different 
parameters investigated when compared with those of respective controls; However, 
the increase or decrease in the values obtained was within normal biological and 
laboratory limits.  
 Results of Biochemical investigations revealed no statistically significant 
changes when compared with those of control. Functional observation tests conducted 
at termination revealed no abnormalities. Urine analysis, conducted at the end of the 
dosing period in week 4 and at the end of recovery period in week 6, revealed no 
abnormality attributable to the treatment. Organ weight data of animals sacrificed at 
the end of the dosing period was found to be comparable with that of respective 
controls. Gross pathological examination did not reveal any abnormality. 
Histopathological examination did not reveal any abnormality. 
CONCLUSION 
 In the present toxicological investigation, no toxic effect was identified upto 
8ml/kg of Karungali Ver Kudineer administered through oral route for 28 days. So, it 
can be concluded that the Karungali Ver Kudineer can be used for therapeutic use in 
human with the dosage recommendations of upto 8ml/kg body weight p.o. 
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Table 1: Dose finding experiment and its behavioral Signs of Toxicity 
No 
Dose 
ml/kg 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
1. 5 + - - + - + - - - - - - - - - - - - - - 
2. 10 + - - + - + - - - - - - - - - - - - - - 
3. 20 + - - + - + - - - - - - - - - - - - -  - 
1. Alertness 2. Aggressiveness 3. Pile erection 4. Grooming  5. Gripping  6. Touch Response 7. Decreased 
Motor Activity 8. Tremors 9. Convulsions 10. Muscle Spasm 11. Catatonia 12. Muscle relaxant 13. Hypnosis 
14. Analgesia 15.Lacrimation 16. Exophthalmos 17. Diarrhoea 18. Writhing 19. Respiration 20. Mortality 
 
 
Table 2. Body wt (g) of rats exposed to Karungali ver Kudineer for 28days. 
Dose 
(ml/kg/day) 
Days 
1 7 14 21 28 
Control 121.41±5.40 122.22±4.62 124.15±5.00 132.15±4.72 135.41±4.00 
2 125.44±4.28 127.20±5.00 130.18±5.11 133.40±5.10 135.14±4.45 
4 128.62±5.12 128.17±4.52 130.21±5.00 132.01±5.02 134.28±5.00 
8 121.18±5.20 125.12±5.20 130.14±5.21 132.00±4.78 135.22±5.12 
Values are mean ± S.E.M. (Dunnet ’t' test). nsP>0.05; Vs Control N=6. 
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Table 3. Food (g/day) intake of rats exposed to Karungali ver Kudineer for 28days. 
Dose 
(ml/kg/day) 
Days (gms/rats) 
1 7 14 21 28 
Control 53.14±2.28 53.44±2.44 55.12±2.11 52.13±2.61 51.15±3.40 
2 54.82±2.12 55.23±2.42 52.42±2.60 55.18±2.45 56.72±3.12 
4 55.13±2.42 52.25±2.30 57.47±2.35 52.46±2.10 51.24±3.16 
8 52.11±2.40 53.40±2.41 59.40±2.22 54.14±2.12 50.10±3.12 
Values are mean ± S.E.M. (Dunnet ’t' test). nsP>0.05; Vs Control N=6. 
 
Table 4. Water intake of rats exposed to Karungali ver Kudineer for 28days. 
Dose 
(ml/kg/day) 
Days(ml/rat) 
1 7 14 21 28 
Control 50.00±2.52 50.25±3.00 51.16±2.88 50.62±3.00 52.15±3.16 
2 50.25±2.34 51.24±3.15 50.56±3.44 48.21±3.40 50.25±2.28 
4 51.40±2.25 50.51±3.45 50.25±3.42 48.13±2.48 52.48±3.45 
8 50.44±3.42 50.40±3.10 55.28±3.25 52.40±3.20 54.44±3.36 
Values are mean ± S.E.M. (Dunnet ’t' test). nsP>0.05; Vs Control N=6. 
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Table 5. Hematological parameters after 28days treatment with Karungali ver 
Kudineer. 
Parameter Control 2ml/kg 4ml/kg 8ml/kg 
RBC (mm3) 7.20±0.33 7.25±0.31 7.18±0.24 7.22±0.28 
HB (%) 14.62±0.27 14.55±0.23 14.72±0.25 14.66±0.32 
Leukocyte 
(x106/mL) 
10.14±1.22 10.12±1.25 10.14±1.24 10.52±1.25 
Platelets (X105/µl) 1.33±0.15 1.30±0.14 1.32±0.12 1.30±0.14 
MCV (g/l) 85.02±4.0 85.00±5.0 85.10±4.15 84.88±5.12 
Neutrophil (%) 52.12±3.2 52.18 ±3.4 51.52±3.2 52.11±3.0 
Lymphocytes (%) 44.14±2.22 45.10±3.0 45.25±2.8 45.21±3.2 
Eosinophil’s (%) 5.0±0.4 5.0±0.4 5±0.3 5±0.3 
Monocytes (%) 3.0±0.02 3.0±0.03 3.0±0.03 3.0±0.02 
Basophils (%) 0±0 0±0 0±0 0±0 
ESR(mm) 1±00 1±00 1±00 1±00 
PCV 45.42±3.12 44.00±3.33 43.00±3.21 43.26±3.15 
Values are mean ± S.E.M. (Dunnet ’t' test). nsP>0.05; Vs Control N=6. 
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Table 6. Effect of treatment with Karungali ver Kudineer biochemical parameters. 
Dose (mg/kg) Control 2ml/kg 4ml/kg 8ml/kg 
Total Bilirubin (mg/dL) 0.211±0.06 0.214±0.04 0.215±0.05 0.215±0.05 
Bilirubin direct 
(mg/dL) 
0.1±0.04 0.1±0.05 0.1±0.04 0.1±0.05 
ALP (U/L) 71.04±2.5 71.21±2.8 71.10±3.0 70.28±2.5 
SGOT (U/L) 74.10±3.2 74.00±3.1 73.11±3.8 74.22 ± 3.4 
SGPT(U/L) 81.1±3.0 82.00±3.2 81.50±2.5 80.14±2.9 
Total Protein(g/dl) 9.00±1.22 9.10±0.23 8.15±0.22 8.21±0.25 
Albumin(g/dl) 3.13±0.20 3.41±0.22 3.40±0.31 3.12±0.30 
Globulin(g/dl) 5.00±0.28 4.78±0.26 4.90±0.24 4.88±0.26 
Urea (mg/dL) 54.40±1.35 54.00±3.00 54.08±2.88 55.01±2.73 
Creatinine (mg/dL) 29.56±3.4 29.11±3.0 28.04±3.14 27.22 ± 3.2 
Uric acid (mg/dL) 1.6±0.18 1.5±0.16 1.7±0.12 1.6±0.15 
Na m.mol 142.42±4.20 142.21±3.00 142.14±3.56 142.00±3.02 
K m.mol 20.02±2.22 19.00±2.19 20.11±2.30 20.18±2.46 
Cl m.mol 102.35±4.88 101.36±5.41 102.60±5.92 101.40±4.00 
Values are mean ± S.E.M. (Dunnet’t' test). nsP>0.05 Vs Control  
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Table-8. Lipid Profile 
Dose (mg/kg) Control 2ml/kg 4ml/kg 8ml/kg 
Total cholesterol (mg/dL) 42.11±2.45 40.27±2.66 41.14±2.64 41.89±2.79 
HDL(mg/dL) 14.22±2.28 14.42±1.84 14.11±1.82 14.00±2.36 
LDL(mg/dL) 42.12±2.62 42.05±3.00 42.55±3.00 42.32±3.24 
VLDL(mg/dl) 16.25±2.33 16.18±2.42 16.22±1.34 15.19±1.20 
Triglycerides (mg/dl) 85.12±2.49 85.21±2.34 85.02±3.04 85.00±2.45 
Blood glucose(mg/dl) 125.23±3.00 125.72±3.12 125.00±3.05 125.82±2.42 
Values are mean ± S.E.M. (Dunnet ’t' test). nsP>0.05; Vs Control N=6. 
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Table-9 Urine Analysis 
Parameters Control 2ml/kg 4ml/kg 8ml/kg 
Colour Yellow Yellow Yellow Yellow 
Transparency Clear Slightly turbid Slightly cloudy Slightly turbid 
Specific gravity 1.010 1.010 1.010 1.010 
PH >7.2 >8.0 >8.0 >9.0 
Protein Nil 3+ 3+ 3+ 
Glucose Nil Nil Nil Nil 
Bilirubin -ve -ve -ve -ve 
Ketones -ve +ve +ve +ve 
Blood Absent Absent Absent Absent 
Urobilinogen Normal Abnormal Abnormal Abnormal 
Pus cells 0-cells/HPF 1-cell/HPF 2-cells/HPF 1-cell/HPF 
RBCs Nil Nil 0-1cells/HPF Nil 
Epithelial cells Nil 1-cell/HPF Nil 1-cell/HPF 
Crystals Nil Nil Nil Nil 
Casts Nil Nil Nil Nil 
Others Bacteria seen Bacteria seen Bacteria seen Bacteria seen 
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Table 10. Effect of Karungali ver Kudineer on organ weight 
Dose (mg/kg) Control 2ml/kg 4ml/kg 8ml/kg 
Liver (g) 7.00±0.10 6.98±0.12 6.90±0.14 7.10±0.15 
Heart (g) 0.62±0.05 0.62±0.05 0.61±0.06 0.63±0.05 
Lung (g) 1.41±0.12 1.42±0.12 1.39±0.11 1.40±0.12 
Spleen (g) 0.64±0.06 0.68±0.05 0.67±0.05 0.68±0.06 
Ovary (g) 1.65±0.12 1.66±0.10 1.65±0.12 1.64±0.14 
Testes (g) 1.40±0.14 1.42±0.11 1.43±0.13 1.44±0.12 
Brain (g) 1.55±0.12 1.56±0.14 1.55±0.11 1.54±0.12 
Kidney (g) 0.70±0.05 0.72±0.05 0.71±0.04 0.72±0.05 
Stomach (g) 1.32±0.15 1.31±0.12 1.32±0.10 1.32±0.15 
Values are mean ± S.E.M. (Dunnet ’t' test). nsP>0.05; Vs Control N=6. 
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BONES                                                       BRAIN 
MINIMAL DOSAGE (2ml) 
                                                      
MODARATE DOSAGE (4ml) 
                                                     
 
HIGH DOSAGE (8ml) 
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HEART                                                             INTESTINES 
MILD DOSE (2ml) 
                 
 
MODARATE DOSAGE (4ml) 
                     
 
HIGH DOSAGE (8ml) 
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KIDNEY                                                      LIVER 
MILD DOSE (2ml) 
                          
MODARATE DOSE (4ml) 
                         
  HIGH DOSE (8ml)                    
                   
 
 
LUNGS                                                          OVARIES 
152 
 
MILD DOSAGE (2ml) 
                   
 
MODARATE DOSAGE (4ml 
                                                        
                         
 
HIGH DOSE (8 ml) 
                              
PANCREAS                                    STOMACH 
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MILD DOSE (2ml) 
                                                                                
                                  
MODARATE DOSE (4 ml) 
                         
HIGH DOSE (8ml) 
 
                              
SPLEEN                                                 TESTIS 
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    MILD DOSE (2ml) 
   
MODARATE DOSE (4ml) 
                       
HIGH DOSE (8ml) 
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ANNEXURE III 
EVALUATION OF ANALGESIC EFFECT OF KARUNGALI VER 
KUDINEER 
INTRODUCTION 
 Pain is a general problem of people throughout the world. Pain is a primary 
response of body injury, inflammation, cancer etc. It can also occur for brain or nerve 
injury. With many pathological conditions, tissue injury is the immediate cause of the 
pain, and this result in the local release of a variety of chemical agents which act on 
the nerve terminals, either activating them directly or enhancing their sensitivity to 
other forms of stimulation. Many plant based traditional siddha medicines propose a 
rich medicinal property used by the population for the treatment of different types of 
pain. However, there were not enough scientific investigations on the analgesic 
activities conferred. One of such drug from Indian system of medicine is Karungali 
ver is an indigenous herb and has been used in for treating rheumatism and 
neuropathic painful conditions. The drug is employed in different forms such as 
decoction, syrup, infusion and powder (Chooranam). Since no scientific data are 
available to justify the traditional analgesic potentials of this drug.  
 Hence, the present study was planned to validate the therapeutic use in 
treatment of painful conditions. Analgesic therapy is dominated by two major classes 
of analgesic drugs; namely opioids and non steroidal anti-inflammatory drugs 
(NSAIDs). Both classes of analgesic drugs produce serious side effects, such as 
gastrointestinal disturbances, renal damages (with NSAIDs drugs), respiratory 
depression and possibly dependence (with opioids). The ultimate aim of the present 
study was to find out the safety and efficacy of the Karungali ver Kudineer which has 
been traditionally used to treat pain. This study was intended to evaluate the peripheral 
and central analgesic activity of Karungali ver Kudineer in experimental animal 
models following oral administration.  
MATERIALS AND METHODS 
Drugs and chemicals 
157 
 
 Acetic acid, and CMC, all from Sigma-Aldrich Chemicals were the chemicals 
used. The standard drugs aspirin and Pentazocine was procured from the local market. 
All the other chemicals and drugs used were of analytical grade. 
Stock solution preparation 
 As recommended in standard siddha literature, the powder form of well dried 
100grams of Karunkali Ver was mixed with 200ml of distilled water. Then this was 
boiled continuously till the total volume is concise to 1/4th as a decoction. The filtered 
supernatant fluid was employed for the preclinical study.  
Animals  
 Albino mice (22–28 g) either sex were obtained from the animal house of 
animal housing facility of department of pharmacology, Vels University, Chennai. 
Animals were maintained at standard laboratory conditions and fed with standard 
feeding pellets (Sai durga foods, Bangalore). Prior to treatment, the animals were 
fasted for 10 and 12 h respectively. However, water was made available ad libitum. 
(Approval number: XIII/VELS/PCOL/05/2000/CPCSEA/IAEC/08.08.2012). 
 
Experimental Methods 
Acute toxicity safety Study 
 Acute oral toxicity test for the Karungaliver Kudineer was carried out as per 
OECD Guidelines 425. As with other sequential test designs, care was taken to ensure 
that animals are available in the appropriate size and age range for the entire study. 
The test substance is administered in a single dose by gavage using a stomach tube or 
a suitable intubation cannula. The fasted body weight of each animal is determined 
and the dose is calculated according to the body weight. After the substance has been 
administered, food was withheld for a further 2 hours in mice. The animals were 
observed continuously for the first 4 h and then each hour for the next 24 h and at 6 
hourly intervals for the following 48 h after administering of the test drug, to observe 
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any death or changes in general behaviour and other physiological activities. Single 
animals are dosed in sequence usually at 48 h intervals.  
 However, the time interval between dosing is determined by the onset, 
duration, and severity of toxic signs. Treatment of an animal at the next dose was 
delayed until one is confident of survival of the previously dosed animal. General 
behavior, respiratory pattern, cardiovascular signs, motor activities, reflexes, change 
in skin and fur, mortality and the body weight changes were monitored daily. The time 
of onset, intensity, and duration of these signs, if any, was recorded.  
Evaluation of analgesic activity by Eddy’s Hotplate method 
 The hot-plate test method was employed to assess the analgesic activity. The 
temperature of the cylinder was set at 55±0.50C. The experimental mice were divided 
into four groups. Each mouse acted as its own control. Prior to treatment, the reaction 
time of each mouse (licking of the forepaws or jumping response) was done at 0 and 
10min interval. The average of the two readings was obtained as the initial reaction 
time. The reaction time following the administration of the Karungaliver Kudineer (1, 
2, 4ml/kg, p.o.), Pentazocine (5mg/kg) and Saline (p.o.), was measured at 30, 60, 90 
and 120 minutes after a latency period of 30 mins. The Percentage analgesic activity 
was calculated. 
Antinociceptive testing 
 The antinociceptive property of Karungaliver Kudineer was tested using the 
model of writhing response in mice. Swiss albino mice of either sexes weighing 20-30 
g were used. The writhing syndrome was elicited by an intraperitoneal injection of 
0.7% acetic acid at the dose of 0.1ml/10 g body weight. For the test group of animals 
Karungaliver Kudineer at the dose level of 1, 2, 4ml/kg, p.o. and for control group 
vehicle saline and Aspirin 100mg/kg was orally administered into the mice 30 min 
before acetic acid and the number of writhes was noted for 15 min beginning 5 min 
after acetic acid injection. 
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Statistical data 
 Data were presented as mean ± S.E.M. Statistical differences between control 
and treated groups were tested by one way ANOVA followed by dunnet’s test. 
RESULTS AND DISCUSSION 
 Karungaliver Kudineer was found safe at all test doses (5, 10 and 20ml/kg 
p.0.). During 24h assessment time, test animals were found normal. Hence the 
therapeutic dose was fixed as 2 and 4ml/kg according to the safety guidelines. Acetic 
acid, which is used as an inducer for writhing syndrome, causes algesia by liberation 
of endogenous substances, which then excite the pain nerve endings. It was found that 
Aspirin caused an effective or significant inhibition on the writhing response induced 
by acetic acid.  
 Doses of 1, 2 and 4ml/kg of the Karungaliver Kudineer were evaluated to 
verify the peripheral analgesic effect. But the results for the animal group treated with 
Karungaliver Kudineer did not differ significantly from negative control. Hence, it is 
assumed that Karungaliver Kudineer has no statistically significant peripheral 
analgesic effect. Therefore, despite of the mild effect observed for the doses of 4ml/kg 
for this test, it was not statistically significant to that of control.  
 Similarly, the result of the analgesic activity evaluated using hot plate method 
revealed that the reaction time for mice was significantly increased in a dose 
dependent manner after 90minutes of oral administration. The Karungaliver Kudineer 
at the both 2&4ml/kg doses remarkably protected the mice against thermally induced 
noxious stimuli, which was evidenced from the hot plate test. Hot plate test was 
assayed to characterize the central analgesic activity. The results showed that the pain 
relief was achieved in a dose dependent manner, at both test doses (1, 2 and 4ml/kg). 
 It is known that non-steroidal anti-inflammatory drugs usually do not increase 
the pain threshold in normal tissues, whereas local anesthetics and narcotics do. The 
acetic acid induced abdominal writhes were observed to be 40.44 ± 6.90 over the 
period of 10 min in the control. The number of abdominal writhes were not 
significantly (p>0.05) inhibited by Karungaliver Kudineer. Standard drug, acetyl 
salicylic acid significantly inhibited writhes by about 73.04% over the control. The 
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pain protective effect exerted by the Karungaliver Kudineer on the mouse by hot plate 
method, suggest that the analgesic effect of the drug may be centrally mediated but 
not peripherally. Acetic acid-induced writhing is a well recommended protocol in 
evaluating medicinal agents for their analgesic property. The pain induction caused by 
liberating endogenous substances as well as some other pain mediators such as 
arachidonic acid via cyclooxygenase, and prostaglandin biosynthesis.  
 This pain paradigm is widely used for the assessment of peripheral analgesic 
activity due to its sensitivity and response to the compounds at a dose which is not 
effective in other methods. The local peritoneal receptor could be the cause of 
abdominal writhings. Pain sensation in acetic acid induced writhing paradigm is 
elicited by producing localized inflammatory response due to release of free 
arachidonic acid from tissue phospholipids via cyclo-oxygenase (COX), and 
producing prostaglandin specifically PGE2 and PGF2α, the level of lipoxygenase 
products may also increases in peritoneal fluids. These prostaglandin and 
lipoxygenase products cause pain by increasing capillary permeability. The substance 
inhibiting the writhings will have analgesic effect preferably by inhibition of 
prostaglandin synthesis, a peripheral mechanism of pain inhibition. Thermal 
nociception models such as hot plate test used to evaluate central analgesic activity.  
CONCLUSION 
 Karungaliver Kudineer showed significant (P<0.01) analgesic effect in the hot 
plate test, implicating supraspinal analgesic pathways. In these pain paradigms 
pentazocin, which is similar to the action of opioid agonists (e.g. morphine), raised the 
pain threshold level within 30min of administration. Karungaliver Kudineer showed 
maximum analgesic effect after 90min of administration. In conclusion, the 
Karungaliver Kudineer was proved as a safe siddha remedy for the treatment of 
algesia at the dose level of 4ml/kg body weight orally. 
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Table 1: Dose finding experiment and its behavioral Signs of Toxicity 
No 
Dose 
ml/kg 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
1. 5 + - - + - + - - - - - - - - - - - - - - 
2. 10 + - - + - + - - - - - - - - - - - - - - 
3. 20 + - - + - + - - - - - - - - - - - - -  - 
1. Alertness 2. Aggressiveness 3. Pile erection 4. Grooming  5. Gripping  6. Touch Response 7. Decreased Motor Activity 8. Tremors 9. Convulsions 10. Muscle 
Spasm 11. Catatonia 12. Muscle relaxant 13. Hypnosis 14. Analgesia 15.Lacrimation 16. Exophthalmos 17. Diarrhoea 18. Writhing 19. Respiration 20. Mortality 
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Table 2: Effect of Karungaliver Kudineer on pain induced by hot plate method 
Treatment Dose Reaction time in sec. 
before drug 
% increase in reaction time after drug treatment 
30min 60min 90min 120min 
Control Saline 2ml/kg 3.2±0.05 8.1±0.02 12.6±0.5 15.48±0.6 15.30±0.5 
Karungaliver Kudineer 1mL/kg 3.2±0.04 19.6±0.32** 25.42±1.18** 37.25±2.23** 35.38±1.12** 
Karungaliver Kudineer 2mL/kg 3.1±0.05 27.2±0.30** 36.20±1.42** 55.39±2.81** 46.20±1.20** 
Karungaliver Kudineer 4mL/kg 2.4±0.05 32.4±0.26** 39.56±1.33** 64.00±2.48** 53.18±1.20** 
Pentazocine 5mg/kg 3.0±0.04 54.1±1.33** 65.72±2.88** 69.10±2.45** 66.04±2.00** 
Values expressed in mean ±SEM, Significant **P<0.01 (n=6) 
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Table –3. Effect of Karungaliver Kudineer on writhing response in mice 
Treatment Dose (mg/kg) Number of writhes Inhibition (%) 
Control Saline 2ml/kg 40.44±6.9 ----- 
Karungaliver Kudineer 1mL/kg 35.18±5.67 13.00 
Karungaliver Kudineer 2mL/kg 33.24±4.00 17.80 
Karungaliver Kudineer 4mL/kg 30.01±2.82 25.79 
Acetyl salicylic acid 100mg/kg 10.9±3.00** 73.04 
Values are expressed as Mean±S.E.M. Drug and test compounds were given orally 30 min before 0.3% acetic acid injection.  
**P<0.01; significantly different from the control group (N=6). 
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ANNEXURE IV 
BIOSTATISTICAL ANALYSIS 
Effect of karungali ver kudineer on HbA1C level (%) in human subjects 
S.NO BEFORE TREATMENT AFTER TREATMENT 
1. 7.6 6.2 
2 7 5.8 
3 7.8 6.4 
4 8.9 7.4 
5 8 6.9 
6 8.3 6 
7 8.2 6.5 
8 9 7 
9 9.3 7.8 
10 9.4 8 
11 8 6.5 
12 8.6 6.4 
13. 8 6.3 
14 7.4 6.2 
15 8.3 6 
16 9 6.8 
17 9.6 8.2 
18 7.3 6.4 
19 8.7 6.8 
20 8.5 7.3 
21 7.9 6.2 
22 8.7 7.5 
23 7.1 6.1 
24 8.4 6.4 
25 7.7 6.9 
26 8.9 7 
27 7.8 6.4 
28 9 7.2 
29 9.6 8.1 
30 7.4 6.3 
31 9.5 7 
32 9.6 8.5 
33 9.7 9 
34 8 6 
35 7.2 6.8 
36 8.6 6 
37 9.3 7.6 
38 7.6 6.1 
39 8.7 5.9 
40 9.8 7.7 
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Software: spss17 version 
Variables: HbA1C levels (%) – before treatment, after treatment 
Number of cases: 40 
Test: Paired t test 
Confidence Interval: 95% 
Correlation coefficient (r): 0.774 
Before and after treatment mean difference: -1.59±0.54 (%) 
P Value (2 tailed): p<0.01 
Inference:  
The p value is significant (p<0.01).  So the treatment was significantly reducing the HbA1C 
level (%). 
Treatment for vatha karsanam 
The most popular statistical tool, namely, Fisher’s Exact Test analysis has been employed to 
analyses the effectiveness with the help of a hypothesis. 
Hypothesis 
There is no reducing symptoms among the patients for the treatment of vatha karsanam 
 
 
 
Symptoms 
Number of cases 
Reduced Not Reduced 
BURNING SENSATION 
NUMBNESS 
WEAKNESS OF LOWER LIMB 
 
24 
88.9% 
 
3 
11.1% 
GLOVE & STOCKING ANASTHESIA 
PAIN IN CALF MUSCLE 
 
8 
61.5% 
 
5 
38.5% 
 
Software: spss17 version 
Number of cases: 40 
Test: Fisher’s Exact test 
Confidence Interval: 95% 
Result: 
P Value (2 tailed): p<0.01 
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Inference:  
Since the p value is significant (<o.o1), The hypothesis is  not accepted. So there is significant 
reduced symptoms among the patients for the treatment of vatha karsanam Hence it is concluded 
that the treatment was effective and significant. 
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CONSENT FORM 
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ANNEXURE V 
CONSENT FORM 
DEPARTMENT OF PG- POTHUMARUTHUVAM 
GOVT SIDDHA MEDICAL COLLEGE CHENNAI-106 
        I certify that I have disclosed all the details about the study in the terms 
readily understood by the patient. 
Date                                                                                                                                 
Signature 
                                                                                                                                  
Name 
                                             
                                                Consent By The Patient 
 
        I have been informed to my satisfaction by the attending physician for the 
purpose of the clinical trial and the nature of the drug treatment and follow up 
including the lab investigation to be performed to monitor and safeguard my 
body functions. 
        I am aware of my right to opd out of the trial at any time during the course 
of the trial without having to give reasons for doing so. 
         I, exercising my free power of choice, hereby give my consent to be 
included as a subject in the clinical trial of KARUNGALI VER KUDINEER  for the 
treatment of VATHA KARSHAANA(DM NEUROPATHY) 
Date                                                              Signature 
                                                              Name : 
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§¿¡Â¡Ç¢Â¢ý ´ôÒ¾ø ÀÊÅõ 
 
 
           ¾¢Õ. ___________________________¬¸¢Â ¿¡ý 
___________ÅÂÐ,         
(_________________________________________________________
_________________________________________________________
___Åº¢ìÌõ þ¼õ.) ±ý ÍÂ ¿¢¨É×¼ý ±Ø¾¢ì ¦¸¡ÎìÌõ ´ôÒ¾ø ÀÊÅõ. 
  
          ¿¡ý Å¡¾¸÷ºÉõ ±ýÛõ §¿¡Â¡ø À¡¾¢ì¸ôÀðÎ ¦ºý¨É,«ÃÍ º¢ò¾ 
ÁÕòÐÅ ¸øæ¡¢Â¢ø (þ¼õ: «È¢ï÷ «ñ½¡ þó¾¢Â ÁÕòÐÅÁ¨É, 
«ÕõÀ¡ì¸õ, ¦ºý¨É-106.) ¿¼ò¾ôÀÎõ º¢ò¾ ÁÕòÐÅ ¬Ã¡öîº¢ ãÄõ 
º¢¸¢î¨º ¦ÀÈ ±ý ÍÂ ¿¢¨É×¼ý ÓØºõÁ¾ò¨¾Ôõ ¦¾¡¢Å¢òÐì¦¸¡û¸¢§Èý. 
 
          þó¾ ¬Ã¡öîº¢Â¢ý §¿¡ì¸õ, ÁÕòÐÅõ ¦ºöÔõ Ó¨È, 
¦¾¡¼÷¸ñ¸¡½¢ôÒ ÁüÚõ ±ý ¯¼ø ¿Äõ ÌÈ¢ò¾ ÁÕòÐÅ 
À¡¢§º¡¾¨É¸¨Çô ÀüÈ¢Â Å¢¡¢Å¡É Å¢Çì¸õ ±ÉìÌ ÁÕòÐÅõ ¦ºöÔõ 
ÁÕòÐÅ÷ ãÄõ ¦¾Ç¢×ÀÎò¾ôÀðÎûÇÐ. þó¾ ¬Ã¡öîº¢Â¢ø ÀíÌ¦¸¡ûÙõ 
±ý ºõÁ¾ò¾¢üÌ Â¡Õ¨¼Â ¿¢÷Àó¾Óõ ¸¡Ã½Á¢ø¨Ä±ýÀ¨¾ 
¦¾¡¢Å¢òÐì¦¸¡û¸¢§Èý. 
 
 
þôÀÊìÌ, 
 
 
¦ÀÂ÷     : 
Ó¸Å¡¢  : 
 
¿¡û      : 
                     ANNEXURE VI 
                                                           
                                                                     CASE SHEET  
POST GRADUATE DEPARTMENT - BRANCH-I 
 (POTHU) MARUTHUVAM  
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GOVT. SIDDHA MEDICAL COLLEGE & ANNA HOSPITAL,    CHENNAI-106. 
CASE SHEET PROFORMA FOR “VATHA KARSANAM” 
WARD NO. : NATIONALITY : 
O.P. NO/ I.P. NO : RELIGION : 
BED NO : OCCUPATION : 
NAME : INCOME : 
AGE : D.O.A : 
SEX : D.OD                            : 
PERMANENT ADDRESS :  
  DIAGNOSIS : 
 
TEMPORARY ADDRESS:  
Govt. Siddha Medical College & 
Anna Hospital, Chennai – 106.                            MEDICAL OFFICER : 
 
 
 
COMPLAINTS AND DURATION : 
 
 
 
 
 
HISTORY OF PRESENT ILLNESS : 
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HISTORY OF PAST ILLNESS 
 
 
 
PERSONAL HISTORY & HABITS : 
A. Food    : Veg   Non veg 
B. Marital status                           : 
FAMILY HISTORY 
 
GENERAL EXAMINATION: 
1. Physical build :      lean             normal            obese  
2. Body weight  : 
3. Temperature  : 
4. Pulse rate : 
5. Heart rate : 
6. Respiratory rate : 
7. Blood pressure  : 
8.  Pallor   : 
9. Cyanosis  : 
10. Jaundice : 
11. Clubbing  : 
12. Pedal oedema : 
13. Lymphadenopathy   : 
14. Acanthosis nigricans : 
15. Hirsutiom :  
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EXAMINATION OF  OTHER SYSTEMS: 
 CARDIO VASCULAR SYSTEM: 
 RESPIRATORY SYSTEM: 
 GASTRO INTESTINAL SYSTEM: 
 CENTRAL NERVOUS SYSTEM: 
1 .MOTOR: 
2 .SENSORY: 
       a. TOUCH                              - 
       b .PAIN                                   - 
      c. TEMPERATURE               -     
      d. POSITION                          - 
      e .VIBRATIONS                     -  
f .CORTICAL SENSE                - 
 
SIDDHA ASPECTS 
Yaakai (udal nilai)      Mukkunam  
1. Vatham        1. Sathuva gunam 
2. Pitham       2. Raasatha gunam  
3. Kapham       3. Thamo gunam 
4. Kalappu 
PARUVA KAALAM (SEASONS)  NILAM (PLACES) 
1. Kaar Kaalam (Aavani-Puratasi) Aug-sept.   1.Kurinchi (Hills  Areas) 
2. Koothir Kaalam (Iypasi-Karthigai) Oct-Nov. 2.Mullai (Forest Areas) 
3. Munpani  Kaalam (Maargazhi-Thai) Dec-Jan. 3.Marudham (Fertile Areas) 
4. Elavenil Kaalam (Chithirai-Vaikasi) Apr-May 4.Neithal (Sea Areas) 
5. Mudhuvenil  Kaalam (Aani-Aadi) Jun-Jul 5.Paalai (Desert Areas) 
 
173 
 
IYAMPORIGAL/PULANGAL  KANMENTHIRIYAM / 
KANMAVIDAYAM 
1. Mei  (Sensation)  1.Kai [Koduthal] 
2. Vaai (Taste)  2.Kaal [Nadathal] 
3. Kann  (Vision)  3.Vaai [Pesal] 
4. Mooku(Smell)  4.Eruvai [Malam Kazhithal] 
5. Sevi (Hearing) 5.Karuvai [Aananthithal] 
MUMMALAM 
1. Malam 
2. Moothiram 
3. Viyaravai 
UYIR THATHUKKAL: 
 Vatham: 
1. Pranan   6.  Naagan 
2. Abanan   7.  Koorman 
3. Viyanan   8.  Kirukaran 
4. Udhanan   9.  Devadathan 
5. Samanan  10. Dhananjeyan 
PITHAM:   KAPHAM: 
1. Anal Pitham  1.  Avalambagam 
2. Ranjaga Pitham   2.  Kledagam 
3. Saadhaga Pitham   3.  Podhagam 
4. Aalosaga Pitham   4.  Tharpagam 
1. Prasaga Pitham  5.  Santhigam 
UDAL THATHUKKAL: 
1. Saaram 
2. Senneer 
3. Oon 
4. Kozhuppu 
5. Enbu 
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6. Moolai 
7. Sukkilam / Suronitham 
Envagai Thervu: 
1. Naa -  
2. Niram 
3. Mozhi -  
4. Vizhi -  
5. Sparisam 
6. Malam 
a. Niram 
b. Nurai 
c. Erugal   
d. Elagal 
e.  
7. Moothiram 
a.  Neerkuri  
1.  Niram 
2. Edai 
3. Manam 
4. Nurai 
5.  Enjal 
b. Neikuri 
8. Naadi  
 
SIGNS AND SYMPTOMS:                          PRESENT ABSENT                                           
MORE THAN 5 YEARS OF DM     
PAIN IN BOTH EXTREMITIES. 
BURNING SENSATIONS IN PALMS &SOLES 
TINGLING  SENSATION 
NUMBNESS 
CALF MUSCLE  TENDERNESS 
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FLACCID WEAKNESS ESPECIALLY IN LOWER LIMBS 
HIGH STEPPING GAIT 
GLOVE & STOCKING TYPE OF ANESTHESIA   
 
Assessment    BEFORE 
TREATMENT 
After Treatment 
                 
I 
          
II 
             
III 
              
IV 
      
MORE THAN 5 YEARS OF DM 
PAIN IN BOTH EXTREMITIES. 
BURNING SENSATIONS IN PALMS &SOLES 
TINGLING  SENSATION 
NUMBNESS 
CALF MUSCLE  TENDERNESS 
FLACCID WEAKNESS ESPECIALLY IN LOWER  
LIMBS 
HIGH STEPPING GAIT 
GLOVE & STOCKING TYPE OF ANESTHESIA 
 
LABORTORY INVESTIGATIONS: 
   BT AT 
1.Blood  Tc 
   Dc 
   ESR 
   Hb 
   Bl-sugar (F)&(PP) 
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   Bl.Urea 
   Sr.Cholesterol 
   Sr.Creatinine 
2.Urine - alb 
   Sug 
   Dep 
3 .MONO FILAMENT TEST: 
4 .NERVE CONDUCTION STUDY: 
TRAIL DRUG: 
KARUNGALI VER KUDINEER 
Dose: 
30ml. twice a day before food… 
Duration of treatment 
Pathiam (Do’s and Don’ts 
Prognosis at the end of the treatment 
 
 
 
Medical Officer Signature:  H.O.D 
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